#1Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Q3 2021 Results Investor presentation 1 Investor Relations | Q3 2021 Results U NOVARTIS | Reimagining Medicine#2Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as "potential," "expected," "will," "planned," "pipeline," "outlook," or similar expressions, or by express or implied discussions regarding potential new products, potential new indications for existing products, potential product launches, or regarding potential future revenues from any such products; or regarding the impact of the COVID-19 pandemic on parts of our business including oncology and generics; or regarding potential future, pending or announced transactions; regarding potential future sales or earnings of the Group or any of its divisions or products; or by discussions of strategy, plans, expectations or intentions; or regarding the Group's liquidity or cash flow positions and its ability to meet its ongoing financial obligations and operational needs; or regarding our in-licensing of tislelizumab from Beigene. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. You should not place undue reliance on these statements. In particular, our expectations could be affected by, among other things: liquidity or cash flow disruptions affecting our ability to meet our ongoing financial obligations and to support our ongoing business activities; the impact of the COVID-19 pandemic on enrollment in, initiation and completion of our clinical trials in the future, and research and development timelines; the impact of a partial or complete failure of the return to normal global healthcare systems including prescription dynamics, particularly in oncology and generics, in the fourth quarter of 2021; global trends toward healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; uncertainties regarding potential significant breaches of data security or data privacy, or disruptions of our information technology systems; regulatory actions or delays or government regulation generally, including potential regulatory actions or delays with respect to the development of the products described in this presentation; the potential that the strategic benefits, synergies or opportunities expected from the transactions described, may not be realized or may be more difficult or take longer to realize than expected; the uncertainties in the research and development of new healthcare products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; safety, quality, data integrity, or manufacturing issues; uncertainties involved in the development or adoption of potentially transformational technologies and business models; uncertainties regarding actual or potential legal proceedings, investigations or disputes; our performance on environmental, social and governance measures; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; uncertainties regarding future global exchange rates; uncertainties regarding future demand for our products; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this presentation as of this date and does not undertake any obligation to update any forward- looking statements as a result of new information, future events or otherwise. Aubagio® is a registered trademark of Sanofi S.A. Tecfidera® is a registered trademark of Biogen MA Inc. 2 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#3Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Participants Vas Narasimhan Chief Executive Officer Harry Kirsch Chief Financial Officer John Tsai Head of Global Drug Development and CMO Richard Saynor CEO, Sandoz Marie-France Tschudin President, Novartis Pharmaceuticals Karen Hale Chief Legal Officer Susanne Schaffert President, Novartis Oncology Samir Shah Global Head Investor Relations 3 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#4Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Vas Narasimhan Chief Executive Officer Company overview 4 Investor Relations | Q3 2021 Results 1 NOVARTIS | Reimagining Medicine#5Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Consistent long-term performance driving confidence for the future - Consistent strong performance since 2018. Confident in our sales growth outlook CAGR 4% to 2025 Sales USD bn, % CAGR CC Core Oplnc USD bn, % CAGR CC Innovative Medicines Core margin (%), growth bps cc +6% 38.4 35.0 35.9 33.3 +13% 12.8 11.9 10.6 9.4 32.4 +220bps 34.3 +90bps +270bps 37.1 36.3 9M 2018 9M 2019 9M 2020 9M 2021 9M 2018 9M 2019 9M 2020 9M 2021 9M 2018 9M 2019 9M 2020 9M 2021 All growth % in cc IM - Innovative Medicines division Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 47 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY 5 Investor Relations | Q3 2021 Results ✓ NOVARTIS | Reimagining Medicine#6Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Solid Q3 performance across our value drivers Growth1 Q3 Group sales +5%; 9M +4% Q3 IM sales +7%; 9M +6% Q3 Sandoz sales -2%; 9M -4% 1 Innovation 177 Lu-PSMA-617 mCRPC post-taxane submission (US) KymriahⓇ r/r FL submission (US, EU) Remibrutinib CSU Ph2b showed rapid, effective disease control CosentyxⓇ GCA Ph2 TitAIN positive readout Canakinumab NSCLC 1L, CANOPY1 Ph3 readout 3 Iptacopan C3G Ph2 final readout (3mo), IgAN addtl analyses (6mo) positive Productivity1 2 ESG Q3 Group core operating income +9%; 9M +4% Positive Ph2b for next generation antimalarial therapy Q3 IM core operating income +13%; 9M +8% Q3 IM core margin 37.8% (+1.9%pts cc); 9M 37.1% Commitment to net zero (2040) with Science-Based Targets Reached ~29m patients in LMICs to date in 2021 through our flagship program and strategic innovative brands All growth % in cc IM - Innovative Medicines division BTD Breakthrough Therapy designation 1. Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 47 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY. 6 Investor Relations | Q3 2021 Results 4 ✓ NOVARTIS | Reimagining Medicine#7Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Key growth drivers and launches continue momentum in Q3 1 GROWTH Q3 sales1 Entresto sacubitril/valsartan Sales USD Million 924 Growth vs. PY USD Million Key growth drivers and launches Growth vs. PY 53% of IM sales, growing 26% in Q3 CC AimovigⓇ 292 44% Cosentyx 1,247 235 22% (secukinumab) Kesimpta 53% +26% vs. PY MayzentⓇ PiqrayⓇ 109 (ofatumumab) JAKAVI 426 ruxolitinib 97 91 108 nm XiidraⓇ 45% 26% KesimptaⓇ LutatheraⓇ zolgensma 375 84 28% 36% KymriahⓇ PROMACTA® 522 (eltrombopag) 80 18% KisqaliⓇ 28% ILARIS 272 52 24% (canakinumab). KISQALI 232 49 27% ribociclib Xolair 365 45 13% Omalizumab MAYZENT. llarisⓇ ZolgensmaⓇ Tafinlar+MekinistⓇ JakaviⓇ PromactaⓇ 76 27 55% (siponimod) tablets KYMRIAH 146 24 20% (tisagenlecleucel) Tafinlar. + Mekinist. 417 20 4% nm - not meaningful Q3 2018 Q3 2019 Q3 2020 *Includes Xolair®, BeovuⓇ, Adakveo®, TabrectaⓇ, Luxturna®, Enerzair, AtecturaⓇ and Leqvio® 1. Innovative Medicines division. Constant currencies (cc) is a non-IFRS measure; explanation of non-IFRS measures can be found on page 47 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY EntrestoⓇ Cosentyx® Q3 2021 Other 7 Investor Relations | Q3 2021 Results ✓ NOVARTIS | Reimagining Medicine#8Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Particularly strong YTD growth for key brands Cosentyx® Entresto zolgensma® KISQALI ribociclib 1 GROWTH Kesimpta USD 3.5bn +18% USD 2.6bn USD 1.0bn +41% +49% USD 0.7bn +27% USD 0.2bn nm All growth rates in constant currencies (cc) 8 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#9Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References 1 GROWTH Raising peak sales guidance for Cosentyx® to at least USD 7bn and EntrestoⓇ to at least USD 5bn CosentyxⓇ Sales evolution (USD bn) Illustrative Q4 Expected peak sales USD ≥ 7bn EntrestoⓇ Sales evolution (USD bn) Illustrative 9M Q4 ✓ Expected 9M 4.0 ✓ Expected 3.6 1.1 1.0 +18% 7.0+ 2.5 2.6 2.9 3.5 1.7 0.7 0.5 +41%1 2.6 1.8 1.2 2019 2020 2021 Peak 2019 2020 2021 Expected peak sales USD ≥ 5bn 5.0+ Peak Market growth, geographic expansion, LCM Market growth driven by increasing use of biologics Geographic expansion continues in China Market penetration, guidelines, geographic expansion Only 30% of HFrEF patients receive EntrestoⓇ ☐ Expansion to 10+ potential indications including HS, LP, LN, GCA 3+ potential formulations and dosing enhancements including i.v. ☐ Expanded label increases eligible US patient population to 5m patients Guidelines positioning EntrestoⓇ as first line therapy Significant opportunity in China and Japan, both including hypertension 1.9M vs PY 9 Investor Relations | Q3 2021 Results 1 NOVARTIS | Reimagining Medicine#10Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References China sales on track to double by 2024 1 GROWTH Group sales evolution USD bn, % cc +18% 0.8 0.7 Strong performance of growth drivers following NRDL inclusion¹ ◉ Solid momentum for Cosentyx® and EntrestoⓇ ■ All key products included in NRDL, outperforming multinational companies by sales growth for those brands ■ Limited exposure to VBP Expanding commercial footprint for additional reach Ramping up activities in lower tier cities and hospitals Increasing cross-functional account management for higher productivity Q3 2020 Q3 2021 ■ Broadening presence in retail and e-pharmacy channels +16% 2.4 1.9 Late stage pipeline to fuel further growth ◉ ◉ ■ EntrestoⓇ HTN, Lucentis® PDR/ROP, Cosentyx® Ped PSO approved in Q3 TafinlarⓇ+MekinistⓇ lung cancer, KisqaliⓇ submitted in Q3 Additional ~50 submissions planned in next 5 years 9M 2020 NRDL National Reimbursement Drug List Cosentyx in Q1/2021 10 Investor Relations | Q3 2021 Results 9M 2021 IL Interleukin HTN Hypertension PDR/ROP - Proliferative Diabetic Retinopathy/ Retinopathy of Prematurity PedPSO - Pediatric Psoriasis 1: EntrestoⓇ NRDL inclusion in Q1/2020, ✓ NOVARTIS | Reimagining Medicine#11Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Sandoz performance ex-US normalizing, growing +3% in Q3 1 GROWTH Q3: Biosimilars, Retail in Europe and ROW gaining share Q3 sales USD 2.4bn (-2% cc) Europe +2% (56% of sales) Bio, Retail, gaining market share ■ ROW +6% (26% of sales) Steady growth across regions, Biosimilars and Retail ■ US -20% (18% of sales) Price erosion, contract terminations Q3 Core Opinc 0.6bn (-15%) Unfavorable gross margin in US Q4: Performance normalizing ex-US as COVID-19 impact decreases Direct demand ■ Different business segments normalizing at different rates ■ Demand impact in Q4 expected to be in line with Q3 Cough & Cold ■ Could start to return to pre-Covid levels in several markets Losartan Negative impact of recall All growth rates in constant currencies unless otherwise stated STO Sandoz Technical Operations 11 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#12Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Commencing strategic review of Sandoz 1 GROWTH Gx market attractive, Sandoz well placed to capitalize on growth drivers over next decade. Preparing for accretive growth with next wave of Biosimilar launches. Attractive market ◉ ☐ Gx business attractive: >USD 400 bn sales LOE over next 10 years (>170 bn in biologics) Gx market estimated CAGR ~4% to 2026 (biosimilar CAGR -9%) Expect gradual post-COVID rebound, particularly antibiotics Strong presence ▪ #1 in Europe, only Gx MNC with top 5 position in all main regions ■ Europe growing, Emerging Markets accelerating, focus to stabilize US ■ Global leadership positions in biosimilars (8 in market), Gx antibiotics, Gx oncology Strategic focus ☐ Biosimilars pipeline doubled¹; 15+ assets in development. Aiming for USD 3bn sales by 2025, USD 5bn by 2030 Complex small molecules: e.g. antibiotics, oncology, respiratory, injectables Ongoing COGS improvements: autonomous Sandoz Technical Operations Aspiration to become global Gx #1, building on brand, reach, scientific and commercial expertise Strategic review to maximize shareholder value: Review will explore all options, ranging from retaining business to separation. Update on progress of the review to be provided latest at the end of 2022. 1. Over last 3 years 12 Investor Relations | Q3 2021 Results 1 NOVARTIS | Reimagining Medicine#13Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References 3 Broad pipeline of novel medicines continued to progress in Q3 Approvals CosentyxⓇ EntrestoⓇ JP, CN: pediatric PsO JP: essential hypertension Readouts and publications (selected) Remibrutinib Ph2 - CSU Canakinumab Ph3 NSCLC 1L1 KisqaliⓇ Cosentyx® Ph3-aBC OS results (MONALEESA-2) Ph2-GCA (TitAIN) Iptacopan Ph2 - C3G Iscalimab Ph2 - kidney Tx KymriahⓇ Ph2 aNHL 2L (BELINDA) BYL719 Real world - PROS (EPIK-P1) Ganaplacide - Ph2b Malaria Negative • Positive Submissions 177Lu-PSMA-617 US: mCRPC, post-taxane US, EU, JP: diabetic macular edema US: 2L ESCC BeovuⓇ Tislelizumab KymriahⓇ Asciminib JP: chronic myeloid leukemia, 3L TafinlarⓇ US: tumor agnostic BRAF mutation US, EU: r/r follicular lymphoma INNOVATION Designations Sabatolimab Asciminib 177 Lu-PSMA-617 LNA043 NIS793 EU orphan drug designation, MDS FDA priority review, CML 3L FDA priority review, mCRPC, post-taxane FDA fast track designation, knee osteoarthritis FDA orphan drug designation, pancreatic cancer 1L See last slide for all abbreviations 1. Post Q3 event. Ph3 study did not meet primary endpoints. PFS and OS trends support further evaluation with additional analyses ongoing 13 Investor Relations | Q3 2021 Results ✓ NOVARTIS | Reimagining Medicine#14Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References 3 INNOVATION Confident in future growth driven by our strength and depth in cardio-renal, immunology, neuroscience... Selected assets Cardio-renal Immunology CosentyxⓇ Neuroscience Ⓡ HS: Ph3 SUNRISE, SUNSHINE readout H2 2021 Zolgensma SMA IT: FDA hold lifted, Ph3 initiating LeqvioⓇ Hyperlipidemia: FDA action date January 1, 2022 GCA: Ph2 readout positive CVRR-LDLC: Ph3 ongoing jPSA/ERA (submitted), lupus nephritis (Ph3), lichen planus (Ph2) Branaplam Huntington's disease: Ph2b start H2 2021 Iptacopan IgAN, C3G, aHUS: Ligelizumab CSU: Ph3 PEARL 1, 2 readout 20211 Ph3s started 2021 iMN: Ph2b ongoing Pelacarsen CVRR-Lp(a): Ph3 ongoing Other indications being explored lanalumab Sjögren's, SLE, Autoimmune hepatitis: Ph2s ongoing Iscalimab Sjögren's, liver Tx, HS: Ph2s ongoing CINDU, food allergy²: Ph3 starts H2 2021 Remibrutinib CSU: Ph2 data positive Remibrutinib Multiple sclerosis: Ph3 start H2 2021 'Wild Cards' LNA043 (osteoarthritis: Ph2 ongoing), CSJ117 (asthma: Ph2 ongoing, COPD Ph2 started), QBW251 (COPD: Ph2 recruitment completed), SAF312 (COSP: Ph2 SAHARA ongoing), UNR844 (presbyopia: Ph2 READER ongoing) 1. Q4/2021-Q1/2022 potential COVID-19 impact 2. Food Allergy indication falls within the Respiratory & Allergy therapeutic area 14 Investor Relations | Q3 2021 Results 1 NOVARTIS | Reimagining Medicine#15Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References and strength and depth in oncology 3 INNOVATION Selected assets Solid tumors Hematology KisqaliⓇ HR+/HER2- BC (adj) NATALEE readout event-driven, expected end 2022 Asciminib CML 3L: submitted CML 1L: Ph3 started Canakinumab 177 Lu-PSMA-617 NSCLC adjuvant: Ph3 ongoing mCRPC post-taxane: submitted Iptacopan PNH: Ph3 started mCRPC pre-taxane: Ph3 started Sabatolimab HR-MDS: Ph2 STIMULUS-MDS-1 continues to PFS readout¹ mHSPC: Ph3 started JDQ443 KRAS inhibitor 2/3L NSCLC: Ph3 start in H1 2022 TNO155 SHP2 inhibitor Solid tumors: multiple combinations being explored in ongoing trials combinations Tislelizumab 2L esophageal cancer: submitted NSCLC: H1 2022 MAA submission, evaluation of US BLA submission options ongoing. Multiple indications in Ph3 YTB323 CD19 CAR-T Ph3 STIMULUS-MDS-2 ongoing AML: Ph2 STIMULUS-AML-1 ongoing r/r DLBCL: Ph2 (pivotal) start 2022 'Wild Cards' LXH254 (melanoma: combo Ph2, NSCLC combo Ph1), NIS793 (mPDAC: Ph3 started, colorectal cancer Ph2 initiating) 1. Planned DMC readout for CR completed, study continues blinded to PFS readout, with submission in 2022/2023 using PFS and/or OS outcomes of Ph2 and/or Ph3 trial 15 Investor Relations | Q3 2021 Results ✓ NOVARTIS | Reimagining Medicine#16Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Remibrutinib maintained robust clinical efficacy throughout treatment period, with fast onset of action in CSU (1/3) Dose-response with significant improvements vs. placebo Rapid and significant improvement in UAS7 over 12 weeks vs. placebo Change from Baseline in UAS7 score 0 -5- -10- -15- -20- -25 max T-Statistics = 6.67, p<0.0001 -30 0 10 20 35 50 100 200 Total Daily Dose (mg) q.d. O b.i.d. q.d. b.i.d. q.d. --- b.i.d. Change from baseline (LS mean + 90% CI) 0 -10- -15- -20 -25 0 1 5 6 7 8 9 10 11 12 Time (Weeks) LOU064 10mg q.d.(N=44) LOU064 25mg b.i.d.(N=43) LOU064 35mg q.d.(N=44) LOU064 100mg b.i.d.(N=45) LOU064 100mg q.d.(N=47) --- Placebo(N=42) LOU064 10mg b.i.d.(N=44) Primary endpoint met; dose-response vs. placebo UAS7 change from baseline at Week 4 No safety signals UAS7 scores improved from baseline up to Week 12 for all doses compared with placebo Improvement was rapid (UAS7) as early as Week 1, and maintained up to Week 12 AE Adverse events CSU - chronic spontaneous urticaria UAS7-weekly Urticaria Activity Score b.i.d. two times a day 16 Investor Relations | Q3 2021 Results 3 INNOVATION NOVARTIS | Reimagining Medicine#17Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Favorable benefit/risk profile across the entire dose range, with no dose-dependent pattern of AEs (2/3) More patients achieved complete control (UAS7=0) UAS7=0 vs. placebo (n=43) Response rate % (90% CI) 100- 90- 80 70 60 50 40- 30- 20 10- 0 1 2 G Placebo(N=42) ■■■■ LOU064 25mg b.i.d.(N=43) 9 10 11 12 Remibrutinib demonstrated good tolerability across the entire dose range tested with no safety signals Key safety data include: ✓ No dose dependent increase of, treatment interruption or discontinuation due to LFT elevations ✓ No dose dependent cytopenias, treatment interruption or discontinuation due to low blood cell counts ✓ No clinically relevant adverse events associated with BTK inhibitor class (e.g. infections, cytopenias, bleeding, hepatic events) across the dose range tested ■ More patients on remibrutinib achieved complete control, i.e. complete absence of hives and itch (UAS7=0) over 12 week treatment period High response rate maintained, up to end of treatment First oral therapy to advance to Ph3 in CSU in 2021 in H1 antihistamines inadequate responders. Best-in-class profile based on positive benefit/risk profile. Ph3 studies in CSU expected to start Q4 2021 AE - Adverse events CSU - chronic spontaneous urticaria UAS7 - weekly Urticaria Activity Score b.i.d. two times a day 17 Investor Relations | Q3 2021 Results 3 INNOVATION 1 NOVARTIS | Reimagining Medicine#18Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Initiating Ph3 trials with remibrutinib in relapsing multiple sclerosis (3/3) Remibrutinib, potential best-in-class potency, selectivity and safety. May offer a more comprehensive and sustained BTK inhibition that allows for maximizing efficacy without compromising patient safety Autoantibodies Immune Complex B cell Receptor BTK inactive Fc Receptor Ksynthesis Kdegradation System-specific properties: Synthesis & degradation BTK BTK active BTK active B cell Myeloid Cell BTK inactive Drug-specific property: Irreversible binding BTK inhibitor remibrutinib Kirrev Cytokines Antigen presentation Inflammatory Mediators Proliferation Cytokines Organ Damage 18 Investor Relations | Q3 2021 Results Irreversible BTK binding ☐ 3 INNOVATION Covalently binds to the intracellular enzyme BTK in B cells and myeloid cells Potent BTK inhibition with brief and low systemic exposure which minimizes risk for AEs and drug-drug interactions CSU data Ph2a trial no dose-limiting side effects in Move directly into Ph3 in MS, with trials to start in Q4 2021 Novartis MS portfolio offers treatment options across the MS spectrum 1 NOVARTIS | Reimagining Medicine#19Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References 3 KisqaliⓇ achieved statistically significant OS benefit in MONALEESA-2 Improvement in median OS was 12.5 months with Kisqali Ⓡ plus letrozole Presented at ESMO 2021 100 80 60 Overall Survival, % 60 40 I 20 20 T Events/n Median OS, mo HR (95% CI) RIB + LET 181/334 63.9 PBO + LET 219/334 51.4 ■ 0.76 (0.63-0.93) P value .004 O 4 8 12 ܘ܂ 16 20 20 - -24 24 28 3 - 32 36 40 40 44 48 52 52 -S 56 60 -80 T -8 - 64 68 72 -2 76 80 60 84 88 Months No. at risk RIB + LET 334 323 315 305 300 284 270 253 237 220 202 191 180 165 158 150 142 PBO+LET 334 326 316 306 293 283 265 244 222 209 195 183 167 149 139 131 114 104 94 73 38 135 125 101 ៨ថ្មី 48 88 8 6 oo 0 0 0 aBC advanced breast cancer 19 Investor Relations | Q3 2021 Results INNOVATION ■ Longest median OS in advanced breast cancer (>5 yrs) Significant survival benefit (>1 yr) ■ + endocrine therapy the only first- line treatment with OS benefit ■ Considered as preferred treatment option for HR+/HER2- ABC Planning to submit this OS data to be incorporated into drug labels NOVARTIS | Reimagining Medicine#20Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References 3 INNOVATION Kisqali® is being investigated in HR+/HER2- early breast cancer (adjuvant) in the Ph3 NATALEE study, expected readout in 2022 NATALEE study design Primary endpoint: invasive disease-free survival (iDFS), event driven Sample size increased to 5000 - more robust RIB Ribociclib 400 mg/day, 3 weeks on/1 week off, 36 months (~ 39 cycles) 36 months Early Breast Cancer (EBC) ■ 83% of breast cancers are diagnosed as EBC ■ EBC treatment objective: cure the patient by preventing disease recurrence while maintaining QoL What makes NATALEE unique? ■ Includes patients with high and intermediate risk of recurrence based on AJCC prognostic staging HR+/HER2- + EBC Pre- and post- R 1:1 ET menopausal Anatomic Stage II & III 20 Investor Relations | Q3 2021 Results ET 60 months NSAI 60 months [+goserelin in pre-menopausal women & men] 60 months NSAI 60 months [+goserelin in pre-menopausal women & men] ■ Longer treatment duration: 3 vs. 2 years ■ Lower dose compared to metastatic setting (400 vs. 600mg) may improve overall tolerability Study status ■ Enrollment complete; readout event-driven and expected late 2022; planned submission 2023 ■ FDA feedback confirms iDFS acceptable as primary analysis provided no detriment in OS NOVARTIS | Reimagining Medicine#21Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References 3 INNOVATION CANOPY-1 Ph3 data support further evaluation of canakinumab in lung cancer CANOPY-1 ■ Did not meet primary endpoints: OS and PFS in previously untreated locally advanced or metastatic NSCLC1 Potentially clinically meaningful improvements in both PFS and OS among pre-specified subgroups of patients with inflammatory biomarkers; additional analyses ongoing1 ■ Results support continued study of canakinumab in earlier stages of lung cancer, further evaluation of Pro-Tumor Inflammation in all lung cancer settings¹. ■ CANOPY-A study more closely reflect the CANTOS study population vs. CANOPY-12,3,4. CANTOS the 1st study to suggest that IL-1ẞ inhibition may play a role in lung cancer³ ■ No unexpected safety signals when combined with pembrolizumab plus platinum-based chemotherapy Study CANOPY-2 2/3 L NSCLC CANOPY-1 1L NSCLC CANOPY-A Adjuvant NSCLC Patient population Metastatic NSCLC treatment failed. Canakimumab with docetaxel Metastatic NSCLC, treatment naive. Canakimumab combined with pembrolizumab Stage II-III NSCLC. Canakimumab after complete resection and adjuvant chemotherapy CANTOS Stable post MI with elevated hsCRP > 2mg/L Hypothesis Reduce progression of treatment resistant tumors Reduce progression of treatment naive tumors Reduce development of tumors from micro- metastatic disease. Findings Primary endpoint OS not met. No benefit observed. Primary endpoints of OS + PFS not statistically significant. Potentially clinically meaningful OS +PFS improvements in pre-specified subgroups (hs-CRP, other biomarker- defined subgroups) To be determined Alter tumor development in high risk population Dose-dependent reduction in fatal/non-fatal lung cancer incidence Developing other potential pro-tumor inflammation pathway inhibitors, which are at various stages of development, incl. gevokizumab5,6 See appendix for references NSCLC Non-small cell lung cancer OS - Overall survival PFS - Progression-free survival 21 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#22Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References 4 ESG Accelerated ESG efforts toward increasing access to medicines, improving health equity and achieving net-zero carbon emissions 1 Access in LMICS Reached nearly 29m patients to date in 2021 through our flagship programs and strategic innovative brands 2 R&D Achieved positive Ph2b for next generation antimalarial therapy ganaplacide in combination with lumefantrine 3 Health equity Announced a planned 10-year commitment with historically black colleges and universities in US to address root causes of systemic disparities in health outcomes 4 Environment Committed to achieving net zero carbon emissions based on Science-Based Targets across our value chain by 2040 22 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#23Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Marie-France Tschudin President, Novartis Pharmaceuticals 23 Investor Relations | Q3 2021 Results 1 NOVARTIS | Reimagining Medicine#24Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Pharmaceuticals grew +8% in Q3 with growth drivers and launches showing strong momentum Growth drivers and launches +32% in Q3, representing 54% of sales (up from 44% Q3 2020) Pharmaceuticals net sales USD bn, % cc Launches1 Growth drivers² Mature products³ +7% +8% 19.7 6.7 17.9 6.1 1.7 0.6 0.4 1.0 +32% +30% 2.3 3.0 6.6 8.4 Representing 54% of sales 3.4 3.1 10.3 9.6 -10% -10% Q3 2020 Q3 2021 9M 2020 9M 2021 All % growth relate to cc unless otherwise stated 1. ZolgensmaⓇ, KesimptaⓇ, MayzentⓇ, BeovuⓇ, LuxturnaⓇ, Leqvio®, Enerzair® and AtecturaⓇ 2. Cosentyx®, EntrestoⓇ, XolairⓇ, llaris®, XiidraⓇ and AimovigⓇ 3. All other brands. 24 Investor Relations | Q3 2021 Results ✓ NOVARTIS | Reimagining Medicine#25Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References CosentyxⓇ grew 22% in Q3; label expansion with pediatric approvals Sales evolution USD m, % cc Ex-US +22% US 1.2bn 1.0bn 494 372 640 753 Q3 2020 Q3 2021 +18% 3.5bn 1.4bn 2.9bn 1.1bn 1.8bn 2.1bn 9M 2021 Strong growth across core indications and markets ■ US: growing volume in line with market across indications vs. Q2 ■ EU: leading biologic in PsO, leading originator biologic in SpA¹ Expanding clinical differentiation with pediatric approvals ■ Ped PSO approval in China 75mg PFS approval in EU for patients <50kg ■ JPSA and ERA indications granted priority review by FDA 9M 2020 Ped PSO Pediatric Psoriasis PsO - Psoriasis SpA - Spondyloarthritis PFS - Pre-filled Syringe jPsA - Juvenile psoriasis arthritis ERA-Enthesitis related rheumatoid arthritis 1. EU patient share data June 2021. 25 Investor Relations | Q3 2021 Results ✓ NOVARTIS | Reimagining Medicine#26Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References CosentyxⓇ peak sales expectations of at least USD 7bn driven by market growth, geographic expansion and LCM In-market indications USD 29bn market growing double-digit¹ Current biologics treated: 15% PsO, 13% axSpA, 23% PSA² China China post-NRDL acceleration with potential to expand to PsA and nr-axSpA Lifecycle management Expansion to 10+ potential indications: Hidradenitis Suppurativa (Ph3 readout Q4), GCA (Ph2 positive, Ph3 started), Lichen Planus (Ph2), Lupus Nephritis (Ph2) Additional potential label enhancements including i.v. for PsA (Ph3 positive) & AS, 300mg autoinjector, Pso flex dosing People + excellence in operations See appendix for references PSO-Psoriasis axSpA - axial Spondyloarthritis nr-axSpA - non-radiographic axial Spondyloarthritis PSA Psoriatic Arthritis NRDL - National Reimbursement Drug List AS - Ankylosing Spondylitis 26 Investor Relations | Q3 2021 Results ✓ NOVARTIS | Reimagining Medicine#27Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References EntrestoⓇ grew +44% in the quarter driven by expanded label in US, guideline 1,2 uptake and strong execution Sales evolution USD m, % cc YTD sales growth vs. PY US +30%, ex-US +53% US weekly NBRx3 New-to-brand prescriptions (000) Ex-US US +44% 924 +41% 2.6bn 5 632 1.8bn 1,407 519 + 318 866 405 314 Q3 2020 Q3 2021 9M 2020 9M 2021 See appendix for references 27 Investor Relations | Q3 2021 Results 3 1,192 915 2 7 01/19 04/19 - 07/19 - 10/19 - 01/20 04/20 - 07/20 - 10/20 - 01/21 - 04/21 - 07/21 - 10/21 - NOVARTIS | Reimagining Medicine#28Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References EntrestoⓇ peak sales expectations of at least USD 5bn driven by remaining patient potential, guidelines, geographic expansion In-market indications ~70% of eligible HFrEF patients not currently treated in G71 US expanded label increased addressable population to 5m Guideline implementation ACC ECDP, ESC and national HF guidelines² recommend ARNI 1L Entresto to replace ACE/ARB in all appropriate HFrEF patients Partnerships to implement quality metrics for HF care Geographic expansion Strong momentum in HFrEF in China Long-term growth in Japan across CHF and HTN Additional growth outside of G7 based on expanded HF label and HTN People + excellence in operations See appendix for references HFrEF - Heart Failure with reduced Ejection Fraction ACC American College of Cardiology ECDP - Expert Consensus Decision Pathway ESC - European Society of Cardiology HF Heart Failure ARNI - Angiotensin Receptor Neprylisin Inhibitor ACE-Angiotensin Converting Enzyme ARB - Angiotensin II Receptor Blocker 28 Investor Relations | Q3 2021 Results ✓ NOVARTIS | Reimagining Medicine#29Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References ZolgensmaⓇ grew 28% in the quarter mainly due to geographic expansion, YTD sales over a billion Sales evolution USD m, %cc Ex-US US YTD sales growth vs. PY Q3 highlights +49% 1.0bn +28% 666 375 658 291 313 249 169 353 351 122 126 Q3 2020 Q3 2021 9M 2020 9M 2021 ■ Growth driven by expanding access in EU, emerging markets ■ Steady US sales continue to be driven by incident patients ■ Access pathways in 23 countries ■ 1.6k+ patients have been treated with ZolgensmaⓇ worldwide¹ 2021 growth drivers ■ Reimbursement: Implementation of recent agreements (i.e. Russia, BeneluxA) ■ Newborn screening: ~84% in US; on track for 20% in EU end 2021 Advancing robust data in SMA ■ STEER (global Ph3 OAV101 IT in patients ages 2-18 with later- onset SMA): anticipate screening first patients by end 2021 ■ SMART (Ph3b study for Zolgensma IV in children up to 21 kg²): rapid enrollment reflects real-world interest and use BeneluxA - Belgium, Netherlands, Luxembourg, Austria 1. Commercially, via managed access programs and in clinical trials 2. SMART is enrolling children ≥ 8.5 kg and ≤ 21 kg 29 Investor Relations | Q3 2021 Results ✓ NOVARTIS | Reimagining Medicine#30Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References KesimptaⓇ accelerating launch momentum driving B-cell market growth Sales evolution USD m, % cc +65% 109 66 ◉ Q2 2021 Q3 2021 Solid launch execution in US Strong contributor to B-cell therapy market growth ■ NBRx share 12.7%1, 2nd highest ahead of AubagioⓇ and TecfideraⓇ ■ >6k patients treated, majority naive or first switch ■ +34% prescribers in the quarter Continuing clinical differentiation ■ ALITHIOS: IgG levels preserved over 3.5 years with low risk of serious infections ■ 94% COVID-19 cases mild / moderate in unvaccinated treated adults Ongoing / initiating studies include immune response to SARS-CoV-2 mRNA vaccines, efficacy and safety of switching from other therapies, investigating PROS in early RMS population in real-world setting IgG Immunoglobulin G PIRA - Progression independent of relapse activity PROS - Patient reported outcomes 1. Unadjusted exit share by end of Q3 30 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#31Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References LeqvioⓇ on track for US launch with FDA action date January 1; As with other cardiovascular launches, expect slow initial ramp Launch preparation Enable health system readiness ■ Ensure protocols in place to identify and manage patients in ~200 prioritized systems Drive awareness among HCPs Education: unmet need, importance of LDL-C ■ Leveraging strong CV footprint Facilitate product acquisition ■ Field team helping to navigate access complexities ■ Network of >1000 AICs to support customers new to buy-and-bill Evidence generation V-INITIATE Explore "Leqvio® first" strategy directly after statins1 V-INCEPTION Investigate Leqvio® initiation after recent ACS events1 H1 2022 expectations ■ High interest from early adopters ■ Independent HCPs ready for buy-and-bill ■ AICS - responding to demand ■ Temporary J-code H2 2022 expectations ▪ Permanent J-code available ■Buy-and-bill capabilities established · System P&T committee review complete ■ Finalization of payer coverage policies See appendix for references HCP Healthcare Professional ASCVD Atherosclerotic Cardiovascular Disease LDL-C - Low Density Lipoprotein Cholesterol AIC - Alternative Injection Center P&T Pharmacy & Therapeutics Committee 31 Investor Relations | Q3 2021 Results ✓ NOVARTIS | Reimagining Medicine#32Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Susanne Schaffert President, Novartis Oncology 32 Investor Relations | Q3 2021 Results 1 NOVARTIS | Reimagining Medicine#33Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Oncology grew 5% in Q3 driven by strong execution Oncology net sales USD bn, % cc +5% 3.9 3.7 0.1 0.1 Launches1 Growth drivers² Base business, Gx³ 10.9 0.3' +4% 11.6 0.4 +17% 1.6 1.9 +16% 4.5 5.4 2.0 1.9 6.0 5.8 -5% -6% Q3 2020 Q3 2021 9M 2020 9M 2021 ■ Growth drivers and recent launches contribute 52% of sales (vs. 47% in Q3 2020) Strong double-digit growth for JakaviⓇ, PromactaⓇ/ RevoladeⓇ and KisqaliⓇ ■ COVID-19 situation normalizing with patient visits, diagnosis and treatment rates increasing, but still below pre-COVID 1. Launches include Piqray®, Adakveo® and TabrectaⓇ 2. Growth drivers include PromactaⓇ/Revolade®, TafinlarⓇ+ MekinistⓇ, KisqaliⓇ, LutatheraⓇ, KymriahⓇ and JakaviⓇ (marketed by Novartis ex-US). 3. Base business - other brands. Gx include AfinitorⓇ, ExjadeⓇ / JadenuⓇ, GlivecⓇ and SandostatinⓇ All % growth relate to cc unless otherwise stated. 33 Investor Relations | Q3 2021 Results ✓ NOVARTIS | Reimagining Medicine#34Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Kisqali® grew +27% in Q3; MONALEESA-2 OS results reinforcing best-in-class profile Sales evolution USD bn, % cc Ex-US US +27% 232 KisqaliⓇ well positioned to become first-choice CDK4/6i ☐ Only CDK4/6i with positive OS results in 3 Ph3 trials ■ MONALEESA-2 unprecedented OS results in largest segment of aBC population Continued growth acceleration, with share gains ex-US ■ Ex-US: Market leader in pre-menopausal setting in EU4 and UK ■ US demand in pre-menopausal and post-menopausal picking up Moving forward with confidence in KisqaliⓇ and its unique profile ■ HARMONIA study to evaluate ribociclib vs. palbociclib in aggressive HER2-enriched intrinsic subtype of HR+/HER2- ABC ■ NATALEE study in eBC completed enrollment in Q2 2021; readout event-driven and expected end 2022 183 145 100 83 87 Q3 2020 Q3 2021 aBC advanced breast cancer eBC early breast cancer 34 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#35Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Continued double-digit growth with PromactaⓇ/Revolade® and JakaviⓇ reflect strong execution PromactaⓇ/Revolade® USD m, % cc Ex-US US JakaviⓇ USD m, % cc +18% +16% 1.5bn 1.3bn 797 657 610 701 9M 2021 963 1.2bn 9M 2020 ■ Most used thrombopoietin receptor agonist with the broadest indication ■ +10% US NBRx share increase¹ driven by sustained efficacy, oral convenience and non-immunosuppressive profile ■ US indication expansion to include persistent ITP expected to fuel further growth MPN Myeloproliferative neoplasms ITP-Immune thrombocytopenia SAA - Severe aplastic anemia 9M 2020 9M 2021 ■ Standard-of-care JAK inhibitor in MPN with proven overall survival and quality of life benefit ◉ ☐ Strong double-digit growth across regions driven by earlier usage in myelofibrosis and polycythemia vera Preparing for launch of acute and chronic GVHD in 2022 GvHD Graft versus host disease 1. Data: IQVIA data, August Rolling 3-month data vs last year August 35 Investor Relations | Q3 2021 Results ✓ NOVARTIS | Reimagining Medicine#36Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Preparing to launch our next growth drivers Scemblix® and 177Lu-PSMA-617 in H1 2022 ■ First STAMP inhibitor, with potential to transform standard of care in CML Asciminib ScemblixⓇ1 ■ Well positioned to launch in 3L CML with 80% pre-launch awareness ■ FDA and EMA 3L CML submission in June 2021 177Lu-PSMA-617 ■ With FDA BTD and Fast Track designation, US approval expected by end of Q1 2022 ■ 1L pivotal study initiated ■ VISION trial showed significant OS and rPFS benefit in advanced mCRPC ■ Awareness campaign on PSMA & Phenotypic Precision Medicine Educating community centers on requirements for RLT ■ With FDA Priority Review, PDUFA expected H1 2022; EMA submission on track ■ Submitted 68 Ga-PSMA-11 kit for PET imaging to FDA, EMA submission on track ☐ Moving into earlier lines with Ph3 studies in mHSPC and mCRPC pre-taxane initiated 1. The brand name ScemblixⓇ has been provisionally approved by the FDA for the investigational product asciminib (ABL001), but the product itself has not been approved for sale in any country PSMA - Prostate-specific membrane antigen FPFV - First patient first visit RLT Radioligand therapy rPFS-Radiographic progression-free survival STAMP - Specifically targeting the ABL myristoyl pocket 36 Investor Relations | Q3 2021 Results ✓ NOVARTIS | Reimagining Medicine#37Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Harry Kirsch Chief Financial Officer Financial review and 2021 guidance 37 Investor Relations | Q3 2021 Results 1 NOVARTIS | Reimagining Medicine#38Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Delivering solid results in the quarter; sales +5%, core Oplnc +9% Group¹ USD million Q3 Change vs. PY 9M Change vs. PY 2021 2021 % USD % cc % USD % CC Net Sales 13,030 6 5 38,397 7 4 Core Operating income 4,467 10 9 12,769 7 4 Operating income 3,233 34 32 9,127 Net Income 2,758 43 41 7,712 29 22 22 18 26 Core EPS (USD) 1.71 13 11 4.88 10 7 EPS (USD) 1.23 45 44 3.44 31 28 Free Cash Flow 4,423 64 10,255 23 1. Core results, constant currencies and free cash flow are non-IFRS measures. Further details regarding non-IFRS measures can be found starting on page 47 of the Condensed Interim Financial Report. All % growth relate to cc unless otherwise stated. 38 Investor Relations | Q3 2021 Results ✓ NOVARTIS | Reimagining Medicine#39Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Driven by strong performance of Innovative Medicines, with double digit core Oplnc growth in the quarter Innovative Medicines Sandoz Group Q3 2021 Core operating 9M 2021 Net sales change vs. PY income 1 change vs. PY Core margin 1 Core margin 1 change vs. PY Net sales change vs. PY (in % cc) (in % cc) (%) (%pts cc) (in % cc) Core operating income 1 change vs. PY (in % cc) Core margin¹ Core margin 1 change vs. PY (%) (%pts cc) 7 13 37.8 1.9 6 8 37.1 0.9 -2 -15 23.8 -3.6 -4 -18 21.6 -3.7 5 9 34.3 1.0 4 4 33.3 0.1 1. Core results, constant currencies and free cash flow are non-IFRS measures. Further details regarding non-IFRS measures can be found starting on page 47 of the Condensed Interim Financial Report. 39 Investor Relations | Q3 2021 Results ✓ NOVARTIS | Reimagining Medicine#40Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References 9M 2021 free cash flow growing to USD 10.3bn Group free cash flow¹ USD bn, % USD 8.3 Key drivers vs. PY: + Higher operating income (adjusted for non-cash items) +23% + 10.3 Lower payments related to legal matters + Favorable working capital + Higher divestment proceeds 9M 2020 9M 2021 Tislelizumab in-licensing (upfront payment USD 650m) 1. Free cash flow is a non-IFRS measure. An explanation of non-IFRS measures can be found on page 47 of the Condensed Interim Financial Report. 40 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#41Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References 2021 Novartis full year guidance Barring unforeseen events; growth vs. PY in cc Sales expected to grow low to mid single digit Group Core Oplnc expected to grow mid single digit, ahead of sales Innovative Medicines Sales expected to grow mid single digit Core Oplnc revised upwards from expected to "grow mid to high single digit" to "grow high single digit" Sales expected to decline low to mid single digit Sandoz Core Oplnc revised downwards from expected to "decline low to mid-teens” to “decline mid to high teens❞ Key assumptions Continuation of the return to normal global healthcare systems including prescription dynamics, in the remainder of the year. In addition, we assume that no GilenyaⓇ and no SandostatinⓇ LAR generics enter in 2021 in the US 41 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#42Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References We expect Q4 to reflect continuation of return to normal healthcare systems. Q1/Q2 impacted by PY COVID-19 stocking/destocking Group quarterly growth vs. PY %pts, constant currency Sales -2 9 Mid 5 single digit Low to Mid single digit Core Operating Income 13 High 9 single digit Mid single digit -8 Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY 42 Investor Relations | Q3 2021 Results Actual Illustrative 1 NOVARTIS | Reimagining Medicine#43Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Expected currency impact for full year 2021 and 2022 5 1 Currency impact vs. PY %pts, assuming late-October exchange rates prevail in 2021 and 2022 0 3 FX impact on Net sales FX impact on Core operating income I I I I I 5 3 2 I 1 2 I I I I I I -1 -1 0 to -1 I -1 to -2 I I FY Q1 -4 I I I I I Q2 Q3 Q4 FY¦ FY FY Q1 Q2 Q3 Q4 FY ¦ FY I I 2020 ¦ I I I I I I 2021 I 2022 2020 2021 2022 Actual Simulation 43 Investor Relations | Q3 2021 Results 1 NOVARTIS | Reimagining Medicine#44Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Vas Narasimhan Chief Executive Officer 44 Investor Relations | Q3 2021 Results 1 NOVARTIS | Reimagining Medicine#45Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Novartis Capital Markets Day, focus R&D December 2, 2021 Virtual Meet Novartis Management May 23-24, 2022 In-person Key R&D assets include: Life-cycle management: Cosentyx LEQVIO KISQALI Power within your reach ribociclib Mid-stage: Pelacarsen, iptacopan, ligelizumab, remibrutinib, canakinumab, 177Lu-PSMA-617, asciminib Early-stage: including technology platforms 45 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#46Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Consistent long-term performance driving confidence for future Novartis delivers solid Q3 results, with strong performance of Innovative Medicines Raised peak sales guidance for Cosentyx® and EntrestoⓇ We remain confident in the strength of our pipeline and launch brands to fuel the growth of our company in the mid to longer term Announced strategic review of Sandoz to maximize shareholder value 46 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#47Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Appendix 47 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#48Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Strong 9M operational performance from growth drivers Key growth driver sales 9M 20211 Driving portfolio rejuvenation 51% AimovigⓇ MayzentⓇ KesimptaⓇ 43% Piqray® XiidraⓇ Sales Growth vs. PY Growth vs. PY USD Million USD Million CC Cosentyx (secukinumab) zolgensma 1,009 Entresto sacubitril/valsartan 2,599 3,475 818 41% Key growth drivers and launches 51% of IM sales, growing 25% YTD 589 18% 343 49% PROMACTA 1,498 231 16% (eltrombopag) Kesimpta 225 224 nm (ofatumumab) 33% JAKAVI® 1,187 ruxolitinib 224 18% KISQALI 652 149 27% 26% ribociclib ILARIS 775 (canakinumab) 142 22% Xolair 1,055 139 10% Omalizumab KYMRIAH 444 111 30% (tisagenlecleucel) Tafinlar +Mekinist 1,235 101 6% 9M 2018 9M 2019 9M 2020 MAYZENT. 200 87 74% (siponimod) tablets nm not meaningful 9M 2021 LutatheraⓇ KymriahⓇ KisqaliⓇ llarisⓇ ZolgensmaⓇ Jakavi® Tafinlar+MekinistⓇ PromactaⓇ EntrestoⓇ CosentyxⓇ Other¹ 1. Includes Xolair®, Beovu®, Adakveo®, TabrectaⓇ, Luxturna Ⓡ, Enerzair ®, AtecturaⓇ and LeqvioⓇ 1. Innovative Medicines division. Constant currencies (cc) is a non-IFRS measure. An explanation of non-IFRS measures can be found on page 47 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year. 48 Investor Relations | Q3 2021 Results U NOVARTIS | Reimagining Medicine#49Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Net debt is broadly in line with December 2020 as FCF was offset by the annual dividend and share buybacks USD bn -24.5 +0.2 -2.9 0.4 -24.3 T -7.4 -0.2 10.3 Dec 31, 2020 Dividends M&A transactions Free Cash Flow Treasury share transactions, net Others Sep 30, 2021 49 Investor Relations | Q3 2021 Results U NOVARTIS | Reimagining Medicine#50Financial review Conclusion Appendix Participants Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview 2021 key pipeline milestones¹ H1 2021 References Innovation: Clinical trials Achieved Readout not supportive Regulatory decisions EntrestoⓇ HFpEF (US) H2 2021 CosentyxⓇ Pediatric psoriasis (US/CN/JP) and opinions KesimptaⓇ Relapsing MS (EU/JP) Major Leqvio® Hyperlipidemia (US)² ✓ Asciminib (ABL001) CML 3L (JP) expected JakaviⓇ submissions TabrectaⓇ Acute and chronic GVHD (EU/JP) ✓ NSCLC (EU) BeovuⓇ DME (JP) Alpelisib (BYL719) BeovuⓇ DME (US/EU) H2 KymriahⓇ Asciminib (ABL001) CML 3L (US/EU) ✓ CosentyxⓇ JIA (US/EU) Major expected trial readouts* Iptacopan (LNP023) Ph2 - IgAN Iptacopan (LNP023) Ph2 - C3G ✓ H2 ECF843 177 Lu-PSMA-617 Tislelizumab (VDT482) Tislelizumab (VDT482) Canakinumab (ACZ885) PROS (US) r/r Follicular lymphoma (US/EU✓ JP) mCRPC (US ✓/EU) 2L esophageal cancer (US) NSCLC (US/EU) Ph3 - NSCLC 1L Ph2 - Dry eye EntrestoⓇ Ph3 - Post-AMI 5 Ligelizumab (QGE031) Ph3 - CSU6 Canakinumab Ph3 NSCLC 2L 7 KisqaliⓇ Ph3 - ABC (MONALEESA-2 OS) (ACZ885) 177Lu-PSMA-617 Cosentyx® Ph3 - mCRPC Ph3 - JIA ✓ Remibrutinib (LOU064) CosentyxⓇ Ph2 - CSU Ph3 - HS ✓ ✓ H1-20223 ✓ 9 ✓ *Achieved Sabatolimab (MBG453) Ph2 - MDS8 KymriahⓇ Ph3 aNHL 2L 7 on-time readout of data, irrespective of trial outcome. 1. 2021 Key milestone table may evolve based on read-out outcomes as well as BD&L activities. 2. Resubmitted to FDA 3. H1 2022 MAA submission, evaluation of US BLA submission options ongoing. 4. Program discontinued in broad population of moderate to severe DED. 5. Numerical trends consistently favored EntrestoⓇ vs. active comparator but did not meet primary composite endpoint. The safety profile of EntrestoⓇ was confirmed. No submission planned. 6. Q4/2021-Q1/2022 potential COVID impact. 7. Negative readout 8. Planned DMC readout for CR completed, study continues blinded to PFS readout, with submission in 2022/2023 using PFS and/or OS outcomes of Ph2 and/or Ph3 trial 9. Ph3 study did not meet primary endpoints. PFS and OS trends support further evaluation with additional analyses ongoing 50 Investor Relations | Q3 2021 Results U NOVARTIS | Reimagining Medicine#51Financial review Conclusion Appendix Participants Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview Our pipeline projects at a glance Oncology Pharmaceuticals Cardiovascular, Renal, Metabolism References Innovation: Clinical trials Phase 1/2 Phase 3 Registration Total 45 27 6 78 55 26 4 85 5 7 1 13 26 26 9 2 37 4 5 0 9 5 1 1 7 8 3 0 11 7 1 0 8 0 2 0 2 Total 100 55 10 165 Immunology, Hepatology, Dermatology Neuroscience Ophthalmology Respiratory & Allergy Global Health Biosimilars 51 Investor Relations | Q3 2021 Results 1 NOVARTIS | Reimagining Medicine#52Participants Financial review Conclusion Appendix Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview Novartis pipeline in Phase 1 (1 of 2) ADPT01 ADPT03 Oncology Code AAA603 Name 177 Lu-NeoB ADPT01 ADPT03 DKY709 DKY709 + spartalizumab HDM201 HDM201 + MBG453, venetoclax JBH492 JBH492 JDQ443 JDQ443 JEZ567 JEZ567 KAZ954 KAZ954 LXF821 LXF821 LXH254 LXH254 MAK683 MAK683 MBG453 MCM998 sabatolimab MCM998, LXG250 MIK665 MIK665 NIS793 NIS793, spartalizumab NIZ985 NZV930 PDR001 PHE885 PHE885 SQZ622 SQZ622 TNO155 TNO155 VAY736 VOB560 VOB560 VPM087 WNT974 ianalumab + ibrutinib gevokizumab WNT974+ spartalizumab WVT078 YTB323 WVT078 YTB323 Mechanism Radioligand therapy target GRPR BCL11A Novel immunomodulatory agent MDM2 inhibitor KRAS Inhibitor CD123 CAR-T EGFR CAR-T CRAF inhibitor EED inhibitor TIM3 antagonist BCMA CAR-T, CD19 CAR-T MCL1 inhibitor TGFB1 inhibitor Indication(s) Multiple solid tumors Colorectal cancer (combos) Sickle cell anemia Cancers Haematological malignancy Haematological malignancy KRAS G12C mutated solid tumors Acute myeloid leukaemia Solid tumors Glioblastoma multiforme NSCLC (combos) Cancers Low risk myelodysplastic syndrome Multiple myeloma Acute myeloid leukaemia (combo) Solid tumors NIZ985, spartalizumab NZV930, spartalizumab, NIR178 spartalizumab IL-15 agonist CD73 antagonist PD1 inhibitor BCMA cell therapy CD123xCD3 modulator SHP2 inhibitor BAFF-R inhibitor - IL-1 beta antagonist Porcupine inhibitor CD19 CAR-T Solid tumors Solid tumors Solid tumors (combo) Multiple Myeloma Acute myeloid leukaemia Solid tumors (single agent) Haematological malignancy Cancers Colorectal cancer, 1st line Solid tumors Multiple myeloma r/r DLBCL and r/r adult ALL 52 Investor Relations | Q3 2021 Results References Innovation: Clinical trials 34 lead indications Lead indication Solid tumors (combo) Solid tumors (combo) NOVARTIS | Reimagining Medicine#53Participants Financial review Conclusion Appendix Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview Novartis pipeline in Phase 1 (2 of 2) Immunology, Hepatology, Dermatology Code Name CEE321 CEE321 FIA586 FIA586 MHS552 MHS552 MHV370 MHV370 Mechanism Pan JAK inhibitor NG1226 NG1226 Neuroscience Code Name LMI070 Branaplam NIO752 NIO752 Indication(s) Atopic dermatitis Non-alcoholic steatohepatitis (NASH) Autoimmune indications Sjögren's Tendinopathy Systemic lupus erythematosus Mechanism Indication(s) mRNA splicing modulator Huntington's disease Tau antagonist Progressive supranuclear palsy Respiratory & Allergy Name Code LTP001 LTP001 NCJ424 NCJ424 Mechanism References Innovation: Clinical trials 34 lead indications Lead indication Indication(s) Respiratory diseases Respiratory diseases Cardiovascular, Renal, Metabolism Code Name MBL949 MBL949 Mechanism Indication(s) Obesity related diseases Global Health Ophthalmology Code MHU650 Name Mechanism Indication(s) KAF156 MHU650 Diabetic eye diseases INE963 Code Name EYU688 EYU688 ganaplacide INE963 Mechanism NS4B inhibitor 53 Investor Relations | Q3 2021 Results Indication(s) Dengue Malaria prophylaxis Malaria, uncomplicated NOVARTIS | Reimagining Medicine#54Participants Financial review Conclusion Appendix Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview Novartis pipeline in Phase 2 Oncology Code ABL001 Name asciminib BYL719 alpelisib BLZ945 BLZ945 DRB436 Tafinlar® + MekinistⓇ TabrectaⓇ INC280 INC424 Jakavi® LXH254 LXH254 MBG453 sabatolimab NIR178 NIS793 NIR178, spartalizumab NIS793 PDR001 spartalizumab PKC412 Rydapte SEG101 AdakveoⓇ Mechanism BCR-ABL inhibitor PI3Ka inhibitor CSF-1R inhibitor BRAF inhibitor + MEK inhibitor Met inhibitor JAK1/2 inhibitor CRAF inhibitor TIM3 antagonist Ad2AR inhibitor, PD1 inhibitor TGFB1 inhibitor PD1 inhibitor Multi-targeted kinase inhibitor P-selectin inhibitor Indication(s) Chronic myeloid leukemia, 2L, pediatrics PIK3CA-related overgrowth spectrum Solid tumors HGG/LGG, pediatrics Non-small cell lung cancer (Combo) Myelofibrosis (combo) Melanoma (combo) Unfit acute myeloid leukaemia Cancers Colorectal cancer (Combos) Metastatic melanoma (combo) Acute myeloid leukemia, pediatrics Sickle cell anaemia with crisis, pediatrics Immunology, Hepatology, Dermatology Code Name ADPT02 ADPT02 Mechanism References Innovation: Clinical trials 24 lead indications Ophthalmology Name Code CPK850 CPK850 LKA651 LKA651 SAF312 libvatrep UNR844 UNR844 Respiratory & Allergy Mechanism RLBP1 AAV EPO inhibitor TRPV1 antagonist Reduction of disulfide bonds Indication(s) Retinitis pigmentosa Diabetic retinopathy Chronic ocular surface pain Presbyopia Acute GVHD, pediatrics Chronic GVHD, pediatrics Code CMK389 CSJ117 Name CMK389 Mechanism IL-18 inhibitor CSJ117 TSLP inhibitor QBW251 icenticaftor QMF149 AtecturaⓇ CFTR potentiator Combo Indication(s) Non-alcoholic steatohepatitis (Combos) AIN457 Cosentyx® IL17A inhibitor Lichen planus CFZ533 iscalimab CD40 inhibitor Sjögren's Liver Tx Hidradenitis CMK389 CMK389 DFV890 DFV890 IL-18 inhibitor Atopic dermatitis NLRP3 inhibitor Osteoarthritis LJN452 tropifexor +licogliflozin LNA043 LNA043 LOU064 remibrutinib FXR agonist Familial cold auto-inflammatory syndrome Non-alcoholic steatohepatitis (Combos) ANGPTL3 agonist BTK inhibitor Knee osteoarthritis Sjögren's Osteoarthritis (combos) LRX712 LRX712 - Osteoarthritis LYS006 LYS006 Anti-inflammatory MAS825 MAS825 VAY736 TIM3 inhibitor ianalumab Acne Colitis ulcerative Hidradenitis NLRC4-GOF indications BAFF-R inhibitor Systemic lupus erythematosus Sjögren's Autoimmune hepatitis 1. Clinical hold lifted 54 Investor Relations | Q3 2021 Results Cardiovascular, Renal, Metabolism Code Name CFZ533 iscalimab HSY244 HSY244 LNP023 iptacopan Neuroscience Code Name BLZ945 BLZ945 MIJ821 MIJ821 Global Health Mechanism CD40 inhibitor CFB inhibitor Lead indication Indication(s) Pulmonary sarcoidosis Asthma Bronchiectasis Chronic obstructive pulmonary disease Chronic obstructive pulmonary disease Asthma, pediatrics Indication(s) Lupus nephritis Type 1 diabetes mellitus Atrial fibrillation Membranous nephropathy Mechanism CSF-1R inhibitor NR2B negative allosteric modulator Indication(s) Amyotrophic lateral sclerosis Depression Code KAE609 KAF156 Name cipargamin ganaplacide Mechanism PfATP4 inhibitor Indication(s) Malaria, severe Malaria, uncomplicated Malaria, uncomplicated LXE408 LXE408 Proteasome inhibitor Visceral leishmaniasis 1 NOVARTIS | Reimagining Medicine#55Participants Financial review Conclusion Appendix Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview Novartis pipeline in Phase 3 Oncology Code Name Mechanism Indication(s) mCRPC, pre-taxane AAA617 177 Lu-PSMA-617 Radioligand therapy target PSMA Metastatic hormone sensitive prostate cancer (mHSPC) AAA6011) LutatheraⓇ Radioligand therapy target SSTR Gastroenteropancreatic neuroendocrine tumors, 1st line in G2/3 BCR-ABL inhibitor tumors (GEP-NET 1L G3) Chronic myeloid leukemia, 1st line References Innovation: Clinical trials 8 lead indications Lead indication Neuroscience Code AMG334 AimovigⓇ BAF312 MayzentⓇ LOU064 remibrutinib OAV101 AVXS-101 OMB157 KesimptaⓇ Name Mechanism CGRPR antagonist S1P1,5 receptor modulator BTK inhibitor Indication(s) Migraine, pediatrics Multiple sclerosis, pediatrics Multiple sclerosis SMN1 gene replacement therapy SMA IT administration CD20 Antagonist Multiple sclerosis, pediatrics ABL001 asciminib ACZ885 canakinumab IL-1b inhibitor BYL719 CTL019 Piqray® KymriahⓇ PI3Ka inhibitor Non-small cell lung cancer (NSCLC), 1L HER2+ adv BC NSCLC, adjuvant Triple negative breast cancer Ovarian cancer Code CD19 CAR-T DRB436 Tafinlar® +Mekinist® BRAF inhibitor + MEK inhibitor 1L high risk acute lymphocytic leukaemia, pediatrics & young adults Thyroid cancer Respiratory & Allergy Name IGE025 XolairⓇ QGE031 ligelizumab Mechanism IgE inhibitor Indication(s) Food allergy Auto-injector IgE inhibitor Food allergy ETB115 PromactaⓇ Thrombopoietin receptor (TPO-R) r/r Severe aplastic anemia agonist INC280 Tabrecta® Met inhibitor Non-small cell lung cancer Cardiovascular, Renal, Metabolism JDQ443 JDQ443 KRAS inhibitor LEE011 Kisqali® CDK4 Inhibitor LNP023 iptacopan CFB inhibitor MBG453 NIS793 sabatolimab NIS793 TIM3 antagonist TGFB1 inhibitor VDT482 tislelizumab PD1 inhibitor YTB323 YTB323 CD19 CAR-T Immunology, Hepatology, Dermatology 2/3L Non-small cell lung cancer HR+/HER2- BC (adj) Paroxysmal nocturnal haemoglobinuria Myelodysplastic syndrome Pancreatic cancer 1L Nasopharyngeal Carcinoma 1L ESCC 1L Hepatocellular Carcinoma 1L Bladder Urothelial Cell Carcinoma 2L r/r Diffuse large B-cell lymphoma 1L Gastric cancer Code Name Mechanism KJX839 Leqvio® LCZ696 Entresto® siRNA (regulation of LDL-C) Angiotensin receptor/neprilysin inhibitor CVRR-LDLC Hyperlipidemia, pediatrics Congestive heart failure, pediatrics²) LNP023 iptacopan CFB inhibitor Non-small cell lung cancer Localized ESCC TQJ230 Pelacarsen ASO targeting Lp(a) C3 glomerulopathy Atypical haemolytic uraemic syndrome Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein (a) (CVRR-Lp(a)) 1L Small Cell Lung Cancer Indication(s) IgA nephropathy Code Name Mechanism Indication(s) Lupus Nephritis AIN457 Cosentyx® IL17A inhibitor QGE031 ligelizumab remibrutinib LOU064 IgE inhibitor BTK inhibitor 1. 177 Lu-dotatate in US. 2. Approved in US. Psoriatic arthritis (IV formulation) Ankylosing spondylitis (IV formulation) Giant cell arteritis Chronic spontaneous urticaria Chronic inducible urticarial (CINDU) Chronic spontaneous urticaria Biosimilars Code Name GP2411 denosumab SOK583 aflibercept Mechanism anti RANKL mAb VEGF inhibitor AS H2H Hidradenitis suppurativa Ophthalmology Code Name RTH258 BeovuⓇ Mechanism VEGF inhibitor Indication(s) Osteoporosis (same as originator) Ophthalmology indication (as originator) Indication(s) Diabetic retinopathy Global Health Code COA566 Name Coartem® Mechanism Indication(s) Malaria, uncomplicated (<5kg patients) 55 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#56Participants Financial review Conclusion Appendix Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview Novartis pipeline in registration Oncology Code Name AAA617 177 Lu-PSMA-617 ABL001 asciminib CTL019 KymriahⓇ INC424 Jakavi® Mechanism Radioligand therapy target PSMA BCR-ABL inhibitor CD19 CAR-T JAK1/2 inhibitor VDT482 tislelizumab PD1 inhibitor Indication(s) Metastatic castration-resistant prostate cancer, post-taxane Chronic myeloid leukemia, 3rd line r/r Follicular lymphoma Acute GVHD Chronic GVHD 2L ESCC Immunology, Hepatology, Dermatology Code AIN457 Name Cosentyx® 1. Approved in EU. Mechanism IL17A inhibitor Indication(s) Cosentyx 300mg auto-injector and pre-filled syringe Juvenile idiopathic arthritis References Innovation: Clinical trials Cardiovascular, Renal, Metabolism Code Name KJX839 Leqvio® Mechanism siRNA (regulation of LDL-C) Indication(s) Hyperlipidemia¹ 4 lead indication Lead indication Ophthalmology Code RTH258 BeovuⓇ Name Mechanism Indication(s) VEGF inhibitor Diabetic macular edema 56 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#57Participants Financial review Conclusion Appendix Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview Novartis submission schedule New Molecular Entities: Lead and supplementary indications NEW INDICATIONS LEAD INDICATIONS 2021 177Lu-PSMA-617 AAA617 mCRPC 3L asciminib ABL001 CML 3L tislelizumab VDT482 2L esophageal cancer 2022 Lead ligelizumab QGE031 2023 Lead iptacopan Lead CSU Lead sabatolimab¹ Lead MBG453 Lead HR-MDS LNP023 PNH References Innovation: Clinical trials 2024 ≥2025 JDQ443 JDQ443 Lead 177 Lu-NeoB Lead ganaplacide Lead LXH254 Lead AAA603 KAF156 Solid tumors (combos) 2/3L NSCLC (mono) Multiple Solid Tumors Malaria uncomplicated remibrutinib Lead LOU064 branaplam LMI070 Lead iscalimab Lead MIJ821 Lead CFZ533 Depression CSU Huntington's disease Sjögren's syndrome UNR844 Lead Lead ianalumab Presbyopia YTB323 Lead 2L r/r Diffuse large B-cell lymphoma VAY736 Sjögren's syndrome CEE321 Atopic Dermatitis cipargamin KAE609 Malaria severe CPK850 RP Lead icenticaftor QBW251 COPD Lead libvatrep SAF312 COSP TQJ230 CVRR-Lp(a) Lead spartalizumab Lead NIS793 Lead 1L Pancreatic cancer Lead pelacarsen Lead Lead PDR001 Metastatic melanoma (combo) CSJ117 Asthma Lead LNA043 Lead TNO155 Lead Knee osteoarthritis Solid tumors gevokizumab VPM087 Lead LXE408 Visceral leishmaniasis 1st line CRC / 1st line RCC Lead tropifexor&licogliflozi Lead LJN452 NASH (combos) tislelizumab VDT482 1L Nasopharyngeal Carcinoma tislelizumab VDT482 NSCLC LCM 177Lu-PSMA-617 LCM AAA617 Pre-taxane LCM iptacopan LNP023 C3G tislelizumab LCM 177Lu-PSMA-617 LCM asciminib LCM iptacopan VDT482 1L ESCC LCM tislelizumab VDT482 AAA617 MHSPC ABL001 CML 1L LCM sabatolimab LCM asciminib MBG453 ABL001 Localized ESCC Unfit AML CML, 2L, pediatrics iptacopan LCM tislelizumab LCM tislelizumab LCM cipargamin LNP023 IgAN tislelizumab VDT482 VDT482 VDT482 KAE609 1L Hepatocellular Carcinoma 1L Small Cell Lung Cancer Malaria uncomplicated LCM 1L Gastric Cancer tislelizumab VDT482 1L Bladder Urothelial Cell Carcinoma LCM ianalumab VAY736 АІН LNP023 aHUS LCM iptacopan LNP023 iMN LCM iscalimab CFZ533 Liver Tx LCM ligelizumab QGE031 Food allergy LCM remibrutinib LOU064 LCM ligelizumab QGE031 CINDU LCM LCM Sjögren's syndrome LCM remibrutinib LCM LOU064 Multiple sclerosis LCM 1. Filing opportunity in 2022 / 2023, based on PFS and/or OS outcomes from a dual approach based on parallel Phase 2 and Phase 3 trials. 57 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#58Participants Financial review Conclusion Appendix Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview Novartis submission schedule Supplementary indications for existing brands References Innovation: Clinical trials 2021 alpelisib BYL719 LCM PROS Beovu LCM brolucizumab, RTH258 DME Cosentyx 2022 secukinumab, AIN457 PSA IVIV Cosentyx secukinumab, AIN457 AS H2H 2023 LCM canakinumab ACZ885 Adjuvant NSCLC LCM Cosentyx 2024 LCM Adakveo SEG101 LCM Atectura LCM Sickle cell anaemia with crisis ped indacaterol + mometasone, QMF149 Asthma, pediatrics ≥2025 Cosentyx secukinumab, AIN457 Lichen Planus LCM Mayzent4 LCM siponimod, BAF312 Multiple sclerosis, pediatrics LCM Coartem LCM Aimovig LCM Jakavi LCM Piqray LCM secukinumab, AIN457 AS IVIV artemether + lumefantrine, COA566 Malaria uncompl., formula for <5kg erenumab, AMG334 ruxolitinib, INC424 alpelisib, BYL719 Pediatric Migraine Myelofibrosis (combination) HER2+ adv BC Cosentyx LCM secukinumab, AIN457 Juvenile idiopathic arthritis Cosentyx secukinumab, AIN457 Hidradenitis suppurativa LCM denosumab BioS Cosentyx LCM aflibercept BioS Kesimpta³ LCM Rydapt LCM GP2411 secukinumab, AIN457 SOK583 ofatumumab midostaurin, PKC412 anti RANKL mAb GCA Neovascular age-related macular degeneration Multiple sclerosis, pediatrics Acute myeloid leukemia, pediatrics Jakavi LCM Entresto EU¹ LCM Kisqali LCM Jakavi LCM Beovu LCM Kymriah LCM Zolgensma LCM ruxolitinib, INC424 sacubitril/valsartan, LCZ696 Chronic GVHD Pediatric CHF Jakavi LCM Tafinlar + Mekinist LCM ribociclib, LEE011 HR+/HER2- BC (adj) Lutathera ruxolitinib, INC424 brolucizumab, RTH258 tisagenlecleucel, CTL019 AVXS-101 OAV101 Pediatrics Acute GVHD Diabetic retinopathy 1L high risk ALL, pediatrics & young adults SMA IT LCM Jakavi LCM Cosentyx LCM Leqvio LCM ruxolitinib, INC424 Acute GVHD dabrafenib + trametinib, DRB436 HGG/LGG - Pediatrics 177 Lu-oxodotreotide² GEP-NET 1L G3 ruxolitinib, INC424 Pediatrics Chronic GVHD secukinumab, AIN457 Lupus Nephritis KJX839 CVRR-LDLC Kymriah LCM Xolair tisagenlecleucel, CTL019 r/r Follicular lymphoma omalizumab, IGE025 Auto-injector LCM Piqray alpelisib, BYL719 TNBC Piqray alpelisib, BYL719 Ovarian cancer Ped Hyperlipidemia LCM Tafinlar + Mekinist LCM Leqvio LCM KJX839 LCM dabrafenib + trametinib, DRB436 Thyroid cancer Promacta LCM eltrombopag, ETB115 r/r severe aplastic anemia Xolair LCM omalizumab, IGE025 Food allergy 1. Approved in US. 2. 177Lu-dotatate in US. 3. Kesimpta and Mayzent: pediatric study in multiple sclerosis run in conjunction (NEOS) 58 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#59Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD Clinical Trials Update Includes selected ongoing or recently concluded global trials of Novartis development programs/products which are in confirmatory development or marketed (typically Phase 2b or later). For further information on all Novartis clinical trials, please visit: www.novartisclinicaltrials.com 59 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#60Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD Cardiovascular, Renal and Metabolic 60 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#61Participants Company overview Pharmaceuticals Financial performance Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations EntrestoⓇ - Angiotensin receptor/neprilysin inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT02678312 PANORAMA HF (CLCZ696B2319) Heart failure in pediatric patients Phase 3 360 Part 1: Pharmacodynamics and pharmacokinetics of sacubitril/valsartan LCZ696 analytes Part 2: Efficacy and safety compared with enalapril Part 1: Sacubitril/valsartan 0.8 mg/kg or 3.1 mg/kg or both; 0.4 mg/kg or 1.6 mg/kg or both (single doses). Part 2: enalapril/placebo 0.2 mg/kg bid (ped. formulation 1mg/ml) and adult formulation (2.5, 5, 10 mg bid); Sacubitril/valsartan (LCZ696)/placebo: Ped. formulation granules (12.5, 31.25 mg in capsules); liquid formulation (1mg/ml and 4mg/ml concentration) and adult formulation (50, 100, 200 mg bid) Pediatric patients from 1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction NCT02884206 PERSPECTIVE (CLCZ696B2320) Heart failure Phase 3 592 Change from baseline in the CogState Global Cognitive Composite Score (GCCS) Sacubitril/valsartan 50, 100, and 200 mg bid with placebo of valsartan Valsartan 40, 80, and 160 mg bid tablets with placebo for sacubitril/valsartan Patients with chronic heart failure with preserved ejection fraction Target Patients Read-out Milesstone(s) 2022; (Analysis of 110 pts from Part 2 formed the basis for pediatric submission in Apr-2019 and approval by the US FDA in Oct-2019 for the treatment of symptomatic HF with systemic left ventricular systolic dysfunction in children aged 1 year and older) 2022 Publication TBD TBD 61 Investor Relations | Q3 2021 Results 1 NOVARTIS | Reimagining Medicine#62Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD Entresto® - Angiotensin receptor/neprilysin inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03785405 (CLCZ696B2319E1 - extension study) Heart failure in pediatric patients Phase 3 240 Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) Single arm, open label sacubitril/valsartan (pediatric formulation granules (12.5, 31.25 mg in capsules); liquid formulation (1mg/ml and 4mg/ml concentration) and adult formulation (50, 100, 200 mg bid)) Pediatric patients with heart failure due to systemic left ventricle systolic dysfunction who have completed study CLCZ696B2319 Target Patients Read-out Milesstone(s) 2023 Publication TBD 62 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#63Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD Leqvio® - Inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT03705234 ORION-4 (CKJX839B12301) Hypercholesterolemia inc. Heterozygous Familial Hypercholesterolaemia (HeFH) Phase 3 ~15000 A composite of major adverse cardiovascular events, defined as: Coronary heart disease (CHD) death; Myocardial infarction; Fatal or non-fatal ischaemic stroke; or Urgent coronary revascularization procedure Arm 1: every 6 month treatment Inclisiran sodium 300mg (given by subcutaneous injection on the day of randomization, at 3 months and then every 6- months) for a planned median duration of about 5 years Arm 2: matching placebo (given by subcutaneous injection on the day of randomization, at 3 months and then every 6-months) for a planned median duration of about 5 years. Patient population with mean baseline LDL-C >= 100mg/dL Read-out Milesstone(s) 2026 Publication TBD 63 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#64Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD Leqvio® - siRNA (regulation of LDL-C) Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT03060577 ORION-3 (CKJX839A12201E1) Hypercholesterolemia inc. Atherosclerotic Cardiovascular Disease (ASCVD) and ASCVD risk equivalents Heterozygous Familial Hypercholesterolaemia (HeFH) Phase 2 490 LDL-C reduction at Day 210 for Group 1 subjects Changes in other lipids and lipoproteins and reduction of LDL-C of more than 50% for patients that are above LDL-C goal; longer term exposure and safety. Group 1 - inclisiran sodium 300mg sc on Day 1 and every 180 days thereafter for up to 4 years. Group 2- Evolocumab 140mg s.c. injection on Day 1 and every 2 weeks until Day 336, followed by inclisiran sodium 300mg on Day 360, Day 450 and then every 6 months for a planned duration of 4 years. Patients with HeFH or pre-existing atherosclerotic cardiovascular disease (ASCVD) on background statin +/- ezetimibe therapy Read-out Milesstone(s) 2022 Publication TBD NCT03814187 ORION-8 (CKJX839A12305B) Hypercholesterolemia inc. Heterozygous Familial Hypercholesterolaemia (HeFH) and Homozygous Familial Hypercholesterolemia (HoFH) Phase 3 2991 Proportion of subjects achieving pre specified low density lipoprotein cholesterol (LDL-C) targets at end of study Safety and tolerability profile of long term use of inclisiran Inclisiran sodium 300mg on day 1 (placebo patients entered into study from ORION 9, 10 & 11) or placebo on Day 1 (inclisiran patients entered into study from ORION 9, 10 & 11) then inclisiran sodium 300mg on Day 90 and every 6 months for a planned duration of 3 years Patients with HeFH or pre-existing atherosclerotic cardiovascular disease (ASCVD) on background statin +/- ezetimibe therapy and risk equivalents (patients from ORION 9, 10 & 11 studies) 2023 TBD 64 Investor Relations | Q3 2021 Results 1 NOVARTIS | Reimagining Medicine#65Participants Company overview Pharmaceuticals Financial performance Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations Leqvio®-siRNA (regulation of LDL-C) Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT03851705 ORION-5 (CKJX839A12302) Hypercholesterolemia inc. Homozygous Familial Hypercholesterolemia (HoFH) Phase 3 56 LDL-C reduction at Day 150 Changes in PCSK9, other lipids and lipoproteins Part 1: inclisiran sodium 300mg on Day 1 and Day 90 or placebo on Day 1 and Day 90 Part 2: inclisiran sodium 300mg on Day 180 for patients who were randomized to the placebo group only, inclisiran sodium 300mg on Day 270 and then every 6 months for a planned duration of 2 years for all patients Patients with HoFH with background statin +/- ezetimibe therapy NCT04652726 ORION-16 (CKJX839C12301) Hyperlipidemia, pediatrics Phase 3 150 Percentage (%) change in low-density lipoprotein cholesterol (LDL-C) from baseline to Day 330 Group 1: Inclisiran sodium 300mg on Days 1, 90, 270, placebo on Day 360, inclisiran sodium 300mg on Days 450 and 630; Group 2: Placebo on Days 1, 90, 270, inclisiran sodium 300mg on Days 360, 450 and 630. Adolescents (12 to less than 18 years) with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDL- Primary: Q3-2020 (actual); Final: H2-2021 Read-out Milesstone(s) Publication TBD 65 Investor Relations | Q3 2021 Results 2023 TBD NOVARTIS | Reimagining Medicine#66Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD LeqvioⓇ - siRNA (regulation of LDL-C) Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT04659863 ORION-13 (CKJX839C12302) Hyperlipidemia, pediatrics Phase 3 15 Percentage (%) change in low-density lipoprotein cholesterol (LDL-C) from baseline to day 330 Group 1: Inclisiran sodium 300mg on Days 1, 90, 270, placebo on Day 360, inclisiran sodium 300mg on Days 450 and 630; Group 2: Placebo on Days 1, 90, 270, inclisiran sodium 300mg on Days 360, 450 and 630. Adolescents (12 to less than 18 years) with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol (LDL- C) Read-out Milesstone(s) 2023 Publication TBD 66 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#67Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD iptacopan - CFB inhibitor Study Indication Phase NCT03832114 (CLNP023X2202) C3 glomerulopathy (C3G) Phase 2 Patients 27 NCT03955445 (CLNP023B12001B) C3 glomerulopathy (C3G) Phase 2 27 Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication Cohort A: Ratio to Baseline of UPCR to Week 12 derived from 24hr urine collection Cohort B: Change from Baseline in C3 Deposit Score (based on immunofluorescence microscopy) at Week 12 Increasing doses of LNP023 up to 200mg bid: Cohort A: Native kidney patients Cohort B: Kidney transplanted patients Patients with C3 glomerulopathy H1-2021 (actual) Actual: Interim analysis data from Cohort-A presented at American Society of Nephrology (ASN 2020). Planned: Note not to be communicated externally until accepted. 1) Planned abstract at ERA-EDTA, Q3 2021 2) Planned abstract at ASN, Q4 2021 Characterize the effect of LNP023 treatment on a composite renal response endpoint at 9 months (1. a stable or improved eGFR and, 2. a reduction in proteinuria and 3. an increase in C3 compared to the CLNP023X2202 baseline visit) Open-label LNP023 200mg bid Patients with C3 glomerulopathy 2025 Wong et al 2021 Nephrology, Dialysis and Transplantation Vol. 36, Suppl. 1: eGFR trajectory 67 Investor Relations | Q3 2021 Results 1 NOVARTIS | Reimagining Medicine#68Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD iptacopan - CFB inhibitor Study Indication Phase NCT04154787 (CLNP023D12201) Idiopathic membranous nephropathy (iMN) Phase 2 NCT04578834 APPLAUSE-IgAN (CLNP023A2301) IgA nephropathy Phase 3 Patients 72 450 Primary Outcome Measures Change from baseline of UPCR derived from 24hr urine collections at Baseline and Week 24 Arms Intervention Ratio to baseline in urine protein to creatinine ratio (sampled from 24h urine collection) at 9 months Annualized total estimated Glomerular Filtration Rate (eGFR) slope estimated over 24 months Arm 1 - LNP023 200mg BID Arm 2 - Placebo BID LNP023 low dose LNP023 high dose Rituximab Patients with biopsy proven iMN who are at high risk of disease progression defined on the basis of antibody anti-PLA2R titre and proteinuria Primary IgA Nephropathy patients Target Patients Read-out Milesstone(s) 2023 Publication TBD 68 Investor Relations | Q3 2021 Results 2023 Perkovic et al. 2021, Nephrology Dialysis Transplantation, Vol. 36, Suppl. 1: Study Design Wong et al. 2021, Nephrology Dialysis Transplantation, Vol. 36, Suppl. 1: IPTACOPAN (LNP023): A NOVEL ORAL COMPLEMENT ALTERNATIVE PATHWAY FACTOR B INHIBITOR SAFELY AND EFFECTIVELY STABILISES EGFR IN C3 GLOMERULOPATHY NOVARTIS | Reimagining Medicine#69Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD iptacopan - CFB inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04817618 APPEAR-C3G (CLNP023B12301) C3 glomerulopathy Phase 3 68 Log-transformed ratio to baseline in UPCR (sampled from a 24 hour urine collection) Experimental: iptacopan 200mg b.i.d. Placebo Comparator: Placebo to iptacopan 200mg b.i.d. Patients with native C3G Target Patients Read-out Milesstone(s) 2023 Publication TBD NCT04889430 APPELHUS (CLNP023F12301) Atypical haemolytic uraemic syndrome Phase 3 50 Percentage of participants with complete TMA response without the use of PE/PI and anti-C5 antibody Single arm open-label with 50 adult patients receiving 200mg oral twice daily doses of iptacopan Adult patients with aHUS who are treatment naive to complement inhibitor therapy (including anti-C5 antibody) 2024 TBD 69 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#70Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD pelacarsen - ASO targeting Lp(a) Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04023552 Lp(a) HORIZON (CTQJ230A12301) Cardiovascular risk reduction Phase 3 7680 Time to the first occurrence of MACE (cardiovascular death, non-fatal MI, non-fatal stroke and urgent coronary re-vascularization) TQJ230 80 mg injected monthly subcutaneously or matched placebo Patients with a history of Myocardial infarction or Ischemic Stroke, or a clinically significant symptomatic Peripheral Artery Disease, and Lp(a) >= 70 mg/dL Target Patients Read-out Milesstone(s) 2024 Publication TBD 70 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#71Participants Company overview Pharmaceuticals Financial performance Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations Immunology, Hepatology & Dermatology 71 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#72Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD LNA043- ANGPTL3 agonist Study Indication Phase Patients Primary Outcome Measures NCT03275064 (CLNA043X2202) Knee osteoarthritis Phase 2 133 Articular cartilage bi-layer collagen organisation evaluated with MRI and measured in milliseconds (ms) (Part A only) Number of patients with any adverse events, serious adverse events and death (Part A and Part B) Change in cartilage volume/thickness in the index region (Part B only) NCT04864392 ONWARDS (CLNA043A12202) Knee osteoarthritis Phase 2 550 Change from baseline in the cartilage thickness of the medial compartment of the knee as assessed by imaging Arms Intervention LNA043 40 mg Part B LNA043 20 mg Part B LNA043 20 mg Part A Placebo Part A Placebo Part B LNA043 injection to the knee with dosing regimen A LNA043 injection to the knee with dosing regimen B LNA043 injection to the knee with dosing regimen C LNA043 injection to the knee with dosing regimen D Placebo injection to the knee Target Patients Patients with cartilage lesions of the knee (Part A) and knee osteoarthritis (Part B) Read-out Milesstone(s) 2022 Patients with Symptomatic knee osteoarthritis Primary 2024 Publication TBD TBD 72 Investor Relations | Q3 2021 Results 1 NOVARTIS | Reimagining Medicine#73Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD Cosentyx® - IL-17A inhibitor Study Indication Phase NCT03031782 (CAIN457F2304) Psoriatic arthritis Phase 3 Patients 80 Primary Outcome Measures Time to 33 flares Arms Intervention Secukinumab (pre-filled syringe) 75 mg Placebo Juvenile idiopathic arthritis subtypes of psoriatic and enthesitis-related arthritis Target Patients Read-out Milesstone(s) H1-2021 Publication H2-2021 NCT03259074 SURPASS (CAIN457K2340) Ankylosing spondylitis Phase 3 837 No radiographic structural progression as measured by modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) Secukinumab 150/300 mg Adalimumab biosimilar 40 mg Patients with active ankylosing spondylitis 2022 Study design manuscript published. Baraliakos et al. Clinical Drug Investigation (2020) 40:269-278. 73 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#74Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD Cosentyx® - IL-17A inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT03713619 SUNSHINE (CAIN457M2301) Hidradenitis Suppurativa (HS) Phase 3 471 Proportion of participants with Hidradenitis Suppurativa clinical response (HiSCR) Secukinumab 300 mg every 2 weeks Secukinumab 300 mg every 4 weeks Placebo (every 2 weeks) Placebo (every 4 weeks) Patients with moderate to severe Hidradenitis Suppurativa Primary (week 16): H2-2021; Final: 2022 Study design SHSA 2020; Primary 2022 NCT03713632 SUNRISE (CAIN457M2302) Hidradenitis Suppurativa (HS) Phase 3 471 Proportion of patients with Hidradenitis Suppurativa Clinical Response (HiSCR) Secukinumab 300 mg every 2 weeks Secukinumab 300 mg every 4 weeks Placebo (every 2 weeks) Placebo (every 4 weeks) Subjects with moderate to severe Hidradenitis Suppurativa Primary (week 16): H2-2021; Final: 2022 Study design SHSA 2020; Primary 2022 74 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#75Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD Cosentyx® - IL-17A inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03769168 (CAIN457F2304E1 - extension study) Psoriatic arthritis Phase 3 64 Number of participants with JIA ACR30 response Secukinumab 75 mg/0.5 ml Secukinumab 150 mg/1.0 ml Patients with juvenile idiopathic arthritis subtypes of juvenile psoriatic arthritis and enthesitis related arthritis Target Patients Read-out Milesstone(s) 2025 Publication TBD NCT04156620 INVIGORATE-1 (CAIN457P12301) Axial spondyloarthritis Phase 3 500 The proportion of subjects achieving an ASAS40 (Assessment of SpondyloArthritis International Society criteria) response Secukinumab intravenous (i.v.) regimen Placebo intravenous (i.v.) regimen Patients with active axial spondyloarthritis Primary (week 16): 2022; Final: 2023 2023 75 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#76Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD Cosentyx® - IL-17A inhibitor Study Indication Phase Patients Primary Outcome Measures NCT04179175 (CAIN457M2301E1) Hidradenitis Suppurativa (HS) Phase 3 745 Proportion of patients with Hidradenitis Suppurativa Clinical Response (HiSCR) Arms Intervention Secukinumab 300 mg every 2 weeks Secukinumab 300 mg every 4 weeks Patients with moderate to severe hidradenitis suppurativa completing either of the core trials AIN457M2301 (NCT 0313632) or AIN567M2302 (NCT03713619) Target Patients Read-out Milesstone(s) 2025 Publication Study design SHSA 2020 NCT04181762 SELUNE (CAIN457Q12301) Lupus Nephritis Phase 3 460 Proportion of subjects achieving protocol-defined CRR Secukinumab 300 mg s.c. Placebo s.c. Patients with active lupus nephritis (ISN/RPS Class III or IV, with or without co- existing class V features) 2026 2026 76 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#77Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD Cosentyx® - IL-17A inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04209205 INVIGORATE-2 (CAIN457P12302) Psoriatic Arthritis (PSA) Phase 3 380 The proportion of subjects achieving American College of Rheumatology 50 (ACR50) response criteria Secukinumab intravenous (i.v.) regimen Placebo intravenous (i.v.) regimen Patients with active psoriatic arthritis (PSA) despite current or previous NSAID, DMARD and/or anti-TNF therapy Target Patients Read-out Milesstone(s) H2-2021 (Actual) Publication 2023 NCT04300296 PRELUDE (CAIN457S12201) Lichen Planus Phase 2 108 Proportion of patients achieving Investigator's Global Assessment (IGA 0/1) score at 16 weeks +30% delta vs placebo Secukinumab 300 mg s.c. Placebo s.c. Adult patients with biopsy-proven lichen planus not adequately controlled by topical therapies 2022 TBD 77 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#78Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD Cosentyx® - IL-17A inhibitor Study Indication Phase Patients Primary Outcome Measures NCT04930094 (CAIN457R12301) Giant cell arteritis Phase 3 240 Arms Intervention Target Patients Read-out Milesstone(s) Publication Number of participants with sustained remission Experimental: Secukinumab 300 mg Placebo Comparator: Placebo Patients with Giant Cell Arteritis (GCA) Primary 2023 Final 2025 TBD 78 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#79Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD ianalumab - BAFF-R inhibitor Study Indication Phase Patients Primary Outcome Measures NCT03217422 AMBER (CVAY736B2201) Autoimmune hepatitis Phase 2 80 Alanine aminotransferase (ALT) normalization Arms Intervention VAY736 Placebo control with conversion to active VAY736 Autoimmune hepatitis patients with incomplete response or intolerant to standard treatment of care Target Patients Read-out Milesstone(s) 2026 Publication TBD 79 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#80Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD iscalimab - CD40 inhibitor Study Indication Phase Patients NCT03781414 CONTRAIL I (CCFZ533A2202) Liver transplantation Phase 2 128 Primary Outcome Measures Arms Intervention NCT03905525 TWINSS (CCFZ533B2201) Sjögren's syndrome Phase 2 260 Proportion of patients with composite event (BPAR, Graft Loss or Death) over 12 months Control/Standard of Care: TAC + MMF + Corticosteroids CFZ533 dose A+ MMF + Corticosteroids CFZ533 dose B + MMF + Corticosteroids Change in EULAR Sjögren's syndrome Disease Activity Index (ESSDAI) score and EULAR Sjögren's syndrome Patient Reported Index (ESSPRI) score Three dose arms of CFZ533 Placebo Target Patients Liver transplant recipients Read-out Milesstone(s) 2023 Publication 2023 80 Investor Relations | Q3 2021 Results Patients with Sjögren's syndrome 2022 2022 NOVARTIS | Reimagining Medicine#81Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD iscalimab - CD40 inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT04541589 TWINSS Extn (CFZ533B2201E1) Sjögren's syndrome Phase 2 Incidence of Treatment-emergent AES (TEAEs) Change in laboratory evaluations for hematology from baseline to each study visit Change in laboratory evaluations for serum chemistry from baseline to each study visit Change in vital sign measurements from baseline for each post-baseline visit Arm 1 Iscalimab Dose 1 s.c. Q2W Arm 2 Iscalimab Dose 2 s.c. Q2W and Placebo Patients with Sjögren's Syndrome, who participated in the TWINSS core study, CCFZ533B2201(NCT03905525) Primary completion date: 2024 81 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#82Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD ligelizumab - IgE inhibitor Study Indication Phase NCT02649218 (CQGE031C2201E1) Chronic spontaneous urticaria / Chronic idiopathic urticaria Phase 2 Patients 226 Long-term safety; number of participants with treatment-emergent adverse events NCT03580356 Pearl 2 (CQGE031C2303) Chronic spontaneous urticarial / Chronic idiopathic urticaria? Phase 3 1050 Absolute change from baseline in UAS7 (Urticaria Activity Score) at week 12 Primary Outcome Measures Arms Intervention Target Patients Ligelizumab 240 mg q4wks open label for 52 weeks Adult patients with chronic spontaneous urticaria inadequately controlled with H1- antihistamines at approved or increased doses, alone or in combination with H2- antihistamines or leukotriene receptor antagonists. Ligelizumab dose A q4w for 52 weeks Ligelizumab dose B q4w for 52 weeks Omalizumab 300 mg q4w for 52 weeks Placebo q4w from randomization to wk20, then ligelizumab dose B from wk24 to wk52 Adolescents and adults with chronic spontaneous urticaria inadequately controlled with H1-antihistamines Read-out Milesstone(s) 2019 (actual) Publication 82 Investor Relations | Q3 2021 Results Manuscript: Primary results extension trial (Allergy), H2 2021 H2-2021 (Q4/2021-Q1/2022 potential COVID impact) Past publications: Study design presented at UCARE 2018 Congress: primary results EADV 2022 (H2 2022) or AAAAI 2023 Manuscript: primary results, Journal (TBD), 2023 1 NOVARTIS | Reimagining Medicine#83Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD ligelizumab - IgE inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT03580369 Pearl 1 (CQGE031C2302) Chronic spontaneous urticaria Phase 3 1050 Absolute change from baseline in UAS7 (Urticaria Activity Score) at week 12 Ligelizumab dose A q4w for 52 weeks Ligelizumab dose B q4w for 52 weeks Omalizumab 300 mg q4w for 52 weeks Placebo q4w from randomization to wk20, then ligelizumab dose B from wk24 to wk52 Adolescents and adults with chronic spontaneous urticaria inadequately controlled with H1-antihistamines H2-2021 (Q4/2021-Q1/2022 potential COVID impact) Past publications: Study design presented at UCARE 2018 Congress: primary results EADV 2022 (H2 2022) or AAAAI 2023 Manuscript: primary results, Journal (TBD), 2023 NCT04210843 (CQGE031C2302E1) Chronic spontaneous urticaria Phase 3 800 The proportion of subjects with well-controlled disease (UAS7 ? 6) at week 12 Ligelizumab Dose 1 and 3 Ligelizumab Dose 2 and 3 Patients who completed studies CQGE031C2302, CQGE031C2303, CQGE031C2202 or CQGE031C1301 2026 Study design presented at 2020 EAACI 83 Investor Relations | Q3 2021 Results 1 NOVARTIS | Reimagining Medicine#84Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD remibrutinib - BTK inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03926611 (CLOU064A2201) Chronic spontaneous urticaria (CSU) Phase 2 308 Change from baseline in weekly Urticaria Activity Score (UAS7) at Week 4 Arm 1 Low dose of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85 Arm 2 Medium dose of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85 Arm 3 High dose of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85 Arm 4 Low dose of LOU064 orally, twice daily from Day 1 to 85 Arm 5 Medium dose of LOU064 orally, twice daily from Day 1 to 85_x0 NCT04109313 (CLOU064A2201E1) Chronic spontaneous urticaria (CSU) Phase 2 250 Long-term safety and tolerability Selected dose of LOU064 taken orally twice a day (morning and evening) from day 1 to week 52 Patients with CSU who have participated in preceding studies with LOU064 Target Patients Adults with CSU inadequately controlled by H1-antihistamines Read-out Milesstone(s) H2-2021 (actual) Publication H2-2021 (EADV) 84 Investor Relations | Q3 2021 Results 2022 TBD 1 NOVARTIS | Reimagining Medicine#85Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD tropifexor, licogliflozin - FXR agonist and SGLT 1/2 inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04065841 ELIVATE (CLJN452D12201C) Non-alcoholic steatohepatitis (NASH) Phase 2 380 Proportion of patients with resolution of NASH and no worsening of fibrosis OR improvement in fibrosis by at least one stage without worsening of NASH at Week 48 compared with baseline Arm A: combination therapytropifexor + licogliflozin Arm B: tropifexor monotherapytropifexor + licogliflozin placebo Arm C: licogliflozin monotherapylicogliflozin + tropifexor placebo Arm D: licogliflozin placebo + tropifexor placebo Adult patients with biopsy based non-alcoholic steatohepatitis (NASH) and liver fibrosis Target Patients Read-out Milesstone(s) Publication 2023 2023 85 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#86Participants Company overview Pharmaceuticals Financial performance Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations Neuroscience 86 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#87Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD MIJ821- NR2B negative allosteric modulator (NAM) Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04722666 (CMIJ821A12201) Major depressive disorder Phase 2 195 Change from baseline to 24 hours in the total score of the Montgomery Åsberg Depression Rating Scale (MADRS) MIJ821 (mg/kg) very low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 Placebo 40 minutes IV infusion of 0.9% sodium chloride on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1 or 0.9% sodium chloride for Participants who have suicidal ideation with intent Target Patients Read-out Milesstone(s) 2023 Publication TBD 87 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#88Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD AimovigⓇ - CGRP receptor antagonist Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT03867201 DRAGON (CAMG334A2304) Migraine Phase 3 550 Change from baseline in monthly migraine days during the last 4 weeks of the 12- week treatment period Subcutaneous injection of AMG334 (erenumab) 70 mg Subcutaneous injection of placebo Adult chronic migraine patients Double-blind FIR for 100% of pts 2021; Q4 2021 Extension (open-label): 2024 Planned in H2-2022 for double-blind phase and H1-2025 for open-label extension phase 88 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#89Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD KesimptaⓇ - CD20 antagonist Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03650114 ALITHIOS (COMB157G2399) Multiple Sclerosis Phase 3 2010 Evaluate the long-term safety and tolerability of ofatumumab 20 mg subcutaneous (sc) once every 4 (94) weeks in subjects with RMS from the first dose of ofatumumab Ofatumumab 20 mg every 4 weeks Patients with relapsing MS Target Patients Read-out Milesstone(s) Publication 2028 TBD 89 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#90Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD MayzentⓇ - S1P1,5 receptor modulator Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT04926818 NEOS (CBAF312D2301) Multiple sclerosis, pediatrics Phase 3 180 Annualized relapse rate (ARR) in target pediatric participants Arm 1: Experimental ofatumumab - 20 mg injection/ placebo Arm 2: Experimental siponimod - 0.5 mg, 1 mg or 2 mg/ placebo Arm 3: Active Comparator fingolimod - 0.5 mg or 0.25 mg/ placebo Children/adolescent patients aged 10-17 years old with Multiple Sclerosis (MS). he targeted enrollment is 180 participants with multiple sclerosis which will include at least 5 participants with body weight (BW) ?40 kg and at least 5 participants with age 10 to 12 years in each of the ofatumumab and siponimod arms. There is a minimum 6 month follow up period for all participants (core and extension). Total duration of the study could be up to 7 years. Read-out Milesstone(s) Publication 90 Investor Relations | Q3 2021 Results 2026 TBD NOVARTIS | Reimagining Medicine#91Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD ZolgensmaⓇ - Gene Therapy Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT03505099 SPR1NT (COAV101A12303) Spinal muscular atrophy Phase 3 30 [2 copies of SMN2] Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit [3 copies of SMN2] Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit Open-label, single-arm, single-dose, intravenous NCT03837184 STRIVE Asia Pacific (COAV101A12304) Type 1 spinal muscular atrophy Phase 3 2 Proportion of participants sitting without support Open-label, single-arm, single-dose, intravenous Patients with spinal muscular atrophy Type 1 H2-2021 Pre-symptomatic patients with spinal muscular atrophy and multiple copies SMN2 H2-2021 (3-copy cohort) Final study results of two-copy cohort were presented as late-breaker oral presentation at EAN Jun 22 2021; final study results of three-copy cohort to be presented at 2022 congress. TBD 91 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#92Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD ZolgensmaⓇ - SMN1 gene replacement therapy Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT03381729 STRONG (COAV101A12102) Type 2 spinal muscular atrophy Phase 1 51 Safety and tolerability, incidence of adverse events Proportion of patients achieving Standing Milestone Change in Hammersmith Functional Motor Scale Open-label, single-arm, single-dose, intrathecal Patients with spinal muscular atrophy with 3 copies of SMN2 Cohort B: Q4-2019 (actual); Cohort C1: TBC Read-out Milesstone(s) Publication TBD 92 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#93Participants Company overview Pharmaceuticals Financial performance Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations Ophthalmology 93 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#94Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD UNR844 - Reduction of disulfide bonds Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT04806503 READER (CUNR844A2022) Presbyopia Phase 2B 225 Characterize the dose response relationship among UNR844 doses 0 mg/mL, 5 mg/mL, 13.3 mg/mL, 23 mg/mL and 30 mg/mL dosed twice-daily after Month 3 of dosing. Change from baseline in Binocular distance-corrected near visual acuity at 40 cm at Month 3. 1:1 randomization - UNR844 0 mg/mL, 5 mg/mL, 13.3 mg/mL, 23 mg/mL and 30 mg/mL dosed twice-daily for three months Presbyopic participants aged 45 to 55 years 2022: Primary endpoint- when all patients have completed the 3 months treatment period 2023: Final analysis -Study completion (all patients have completed 9 months pots treatment period) TBD 94 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#95Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD BeovuⓇ - Anti-VEGF Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03386474 (CRTH258A2301E1) Neovascular age-related macular degeneration (nAMD) Phase 3 NCT04005352 TALON (CRTH258A2303) Neovascular Age-related Macular Degeneration (nAMD) Phase 3B 150 Number of treatment-emergent adverse events Brolucizumab (RTH258) 6 mg/50 μL Aflibercept 2 mg/50 μL Patients with neovascular age-related macular degeneration who have completed the CRTH258A2301 study Average change in Best-corrected visual acuity Distribution of the last interval with no disease activity (in a Treat-to-Control regimen) Arm 1: Brolucizumab 6 mg intravitreal injection Arm 2: Aflibercept 2 mg intravitreal injection Patients with Neovascular Age-related Macular Degeneration (nAMD) who have not previously received anti-VEGF (vascular endothelial growth factor) treatment Target Patients Read-out Milesstone(s) 2018 (actual) Publication Manuscript planned for submission H2-2021 95 Investor Relations | Q3 2021 Results 2022 TBD NOVARTIS | Reimagining Medicine#96Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD BeovuⓇ - Anti-VEGF Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04047472 HOBBY (CRTH258A2307) Macular degeneration Phase 3 494 Change from baseline in best-corrected visual acuity (BCVA) at week 48 Brolucizumab (RTH258) 6 mg/50 μL Aflibercept 2 mg/50 μL Chinese patients with neovascular age-related macular degeneration Target Patients Read-out Milesstone(s) 2024 Publication TBD 96 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#97Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD BeovuⓇ - VEGF Inhibitor Study Indication Phase NCT03481634 KESTREL (CRTH258B2301) Diabetic eye disease Phase 3 Patients 534 Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication Change from baseline in best-corrected visual acuity (BCVA) Brolucizumab (RTH258) 3 mg/50 μL Brolucizumab (RTH258) 6 mg/50 μL Aflibercept 2mg/50 uL Patients with visual impairment due to diabetic macular edema (DME) Primary: Q4-2020 (actual); Final: Q4-2021 Brown et al., presented at ARVO May 2021 Manuscript submission H2 2021 NCT03481660 KITE (CRTH258B2302) Diabetic eye disease Phase 3 356 Change from baseline in best-corrected visual acuity (BCVA) Brolucizumab (RTH258) 6 mg/50 μL Aflibercept 2 mg/50 μL Patients with visual impairment due to diabetic macular edema (DME) Primary: Q3-2020 (actual); Final: Q3-2021 (actual). Brown et al., presented at ARVO May 2021 Manuscript submission H2 2021 97 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#98Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD BeovuⓇ - VEGF Inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03917472 KINGFISHER (CRTH258B2305) Diabetic macular edema Phase 3 500 Change in best-corrected visual acuity (BCVA) from baseline up to week 52 Brolucizumab (RTH258) 6 mg/50 μL Aflibercept 2 mg/50 μL Target Patients Patients with visual impairment due to diabetic macular edema Read-out Milesstone(s) Q3-2021 (Actual) Publication Publication planned for H1-2022 NCT04058067 KINGLET (CRTH258B2304) Diabetic macular edema Phase 3 268 Change in best-corrected visual acuity (BCVA) Brolucizumab (RTH258) 6 mg/50 μL Aflibercept 2 mg/50 μL Chinese patients with visual impairment due to diabetic macular edema 2023 Publication planned for 2023 98 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#99Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD BeovuⓇ - VEGF Inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04278417 (CRTH258D2301) Diabetic retinopathy Phase 3 706 Change from Baseline in BCVA Arm 1: RTH258 (Brolucizumab) 6 mg3 x q6w loading injections, followed by q12w maintenance through week 90 Arm 2: Panretinal photocoagulation laser initial treatment in 1-4 sessions up to Week 12, followed with additional PRP treatment as needed Patients with proliferative diabetic retinopathy Target Patients Read-out Milesstone(s) 2024 Publication TBD 99 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#100Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD libvatrep - TRPV1 antagonist Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04630158 SAHARA (CSAF312B12201) Chronic ocular surface pain Phase 2 150 Change in mean pain severity Visual Analog Scale Placebo Comparator: SAF312 Placebo. Randomized to a 1:1:1 topical eye drops, twice daily Experimental: SAF312 dose 1. Randomized to a 1:1:1 topical eye drops, twice daily Experimental: SAF312 dose 2. Randomized to a 1:1:1 topical eye drops, twice daily Subjects with CICP persisting at least for 4 months after refractive surgery and chronicity confirmed during the observational period. Target Patients Read-out Milesstone(s) Publication 2023 2023 100 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#101Participants Company overview Pharmaceuticals Financial performance Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations Respiratory & Allergy 101 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#102Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD CSJ117 - Inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04410523 (CCSJ117A12201C) Asthma Phase 2 625 Pre-dose FEV1 (Forced Expiratory Volume in 1 second) change from baseline after 12 weeks of treatment. Average change from baseline in pre-dose FEV1 at week 8 & week 12 CSJ117 0.5mg CSJ117 1mg CSJ117 2 mg CSJ117 4 mg CSJ117 8 mg Placebo Asthma patients on background medium or high ICS plus LABA therapy Target Patients Read-out Milesstone(s) Publication 2022 Primary publications planned for 2022 102 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#103Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD icenticaftor - CFTR potentiator Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04072887 (CQBW251B2201) Chronic obstructive pulmonary disease (COPD) Phase 2 956 Trough FEV1 (Forced Expiratory Volume in 1 second) change from baseline after 12 weeks of treatment QBW251 450 mg QBW251 300 mg QBW251 150 mg QBW251 75 mg QBW251 25 mg Placebo COPD patients on background triple inhaled therapy (LABA / LAMA / ICS) Target Patients Read-out Milesstone(s) Publication 2022 Primary publications planned for 2022 103 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#104Participants Company overview Pharmaceuticals Financial performance Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations Oncology: Solid Tumors 104 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#105Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD alpelisib - PI3K-alpha inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT04589650 EPIK-P2 (CBYL719F12201) PIK3CA-related overgrowth spectrum Phase 2 150 Proportion of participants with a response at Week 24 Arm 1: alpelisib vs. Arm 2: placebo during the 16 first weeks, for each cohort (adult, pediatric), with placebo patients switching to alpelisib thereafter. Pediatric and adult participants with PIK3CA-related overgrowth spectrum (PROS) Primary Analysis: H1-2023 NA 105 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#106Participants Company overview Pharmaceuticals Financial performance Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations canakinumab - IL-1 beta inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT03631199 CANOPY-1 (CACZ885U2301) 1st Line Non-small cell lung cancer (NSCLC) Phase 3 627 Safety run-in part: Incidence of dose limiting toxicities Double-blind, randomized, placebo-controlled part: Progression free survival (PFS) Overall survival (OS) Canakinumab or matching placebo in combination with pembrolizumab and platinum-based doublet chemotherapy Patients with Histologically confirmed Stage IIIB, IV NSCLC with no prior systemic anticancer therapy Squamous and non-squamous NSCLC No EGFR mutation and ALK rearrangement H2-2021 Johnson B et al. Presented at AACR-NCI-EORTC 2019 (safety run-in) Planned abstract submission to congress in 2H 2021 106 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#107Participants Company overview Pharmaceuticals Financial performance Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations canakinumab - IL-1 beta inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT03447769 CANOPY-A (CACZ885T2301) Adjuvant NSCLC Phase 3 1500 Disease free survival (primary), overall survival (key secondary) Canakinumab 200mg q3w sc for 18 cycles Placebo q3w sc for 18 cycles Patients with: High-risk NSCLC (AJCC/UICC v.8 stage II-IIIA and IIIB (T>5cm N2)) after complete resection and standard of care adjuvant cisplatin-based chemotherapy All histologies Read-out Milesstone(s) Publication 2023 TBD 107 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#108Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD NIS793 - TGFẞ1 inhibitor Study Indication Phase Patients Primary Outcome Measures NCT04935359 (CNIS793B12301) 1L Pancreatic cancer Phase 3 490 ☐ Arms Intervention " Safety run-in part: Percentage of participants with dose limiting toxicities (DLTs) during the first cycle (4 weeks) of treatment Randomized part: Overall survival (OS) Arm 1: Experimental: Safety run-in part: NIS793+gemcitabine+nab-paclitaxel In the safety run-in part, participants will receive a combination of NIS793, gemcitabine and nab-paclitaxel " Arm 2: Experimental: Randomized part: NIS793+gemcitabine+nab-paclitaxel Participants will receive a combination of NIS793, gemcitabine and nab-paclitaxel Arm 3: Placebo Comparator: Randomized part: placebo+gemcitabine+nab- paclitaxel " Participants will receive a combination of placebo, gemcitabine and nab-paclitaxel Patients with Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC), first line treatment Target Patients Read-out Milesstone(s) 2026 Publication TBD 108 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#109Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD TNO155 - SHP2 inhibitor Study Indication Phase Patients Primary Outcome Measures NCT03114319 (CTNO155X2101) Solid tumors (single agent) Phase 1 255 Number of participants with adverse events Number of participants with dose limiting toxicities Arms Intervention Drug: TNO155 Drug: TNO155 in combination with EGF816 (nazartinib) Adult patients with advanced solid tumors in selected indications Target Patients Read-out Milesstone(s) 2023 Publication TBD 109 Investor Relations | Q3 2021 Results NCT04000529 (CTNO155B12101) Solid tumors (combo) Phase 1 126 Incidence of dose limiting toxicities (DLTs) during the first cycle of combination treatment during the dose escalation part Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as per CTCAE v5.0, by treatment Dose tolerability TNO155 and Spartalizumab (PDR001) TNO155 and Ribociclib (LEE011) Patients with advanced malignancies 2022 TBD NOVARTIS | Reimagining Medicine#110Participants Company overview Pharmaceuticals Financial performance Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations 177Lu-PSMA-617 - Radioligand therapy target PSMA Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) NCT04689828 PSMAfore (CAAA617B12302) Metastatic castration-resistant prostate cancer, pre-taxane Phase 3 450 Radiographic Progression Free Survival (rPFS) Arm 1: Participants will receive 7.4 GBq (200 mCi) +/- 10% 177Lu-PSMA-617 once every 6 weeks for 6 cycles. Best supportive care, including ADT may be used Arm 2: For participants randomized to the ARDT arm, the change of ARDT treatment will be administered per the physician's orders. Best supportive care, including ADT may be used mCRPC patients that were previously treated with an alternate ARDT and not exposed to a taxane-containing regimen in the CRPC or mHSPC settings Primary Analysis: 2022 Final Analysis: 2025 NCT04720157 PSMAddition (CAAA617C12301) Metastatic hormone sensitive prostate cancer Phase 3 1126 Radiographic Progression Free Survival (rPFS) Arm 1: 177Lu-PSMA-617 Participant will receive 7.4 GBq (+/- 10%) 177Lu-PSMA- 617, once every 6 weeks (+/- 1 week) for a planned 6 cycles, in addition to the Standard of Care (SOC); ARDT +ADT is considered as SOC and treatment will be administered per the physician's order Arm 2: For participants randomized to Standard of Care arm, ARDT +ADT is considered as SOC and treatment will be administered per the physician's order Patients with metastatic Hormone Sensitive Prostate Cancer (mHSPC) Primary Analysis: 2024 Publication TBD 110 Investor Relations | Q3 2021 Results TBD 1 NOVARTIS | Reimagining Medicine#111Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD KisqaliⓇ - Inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03701334 NATALEE (CLEE011012301C) Adjuvant treatment of hormone receptor (HR)-positive, HER2-negative, early breast cancer (EBC) Phase 3 5101 Invasive Disease-Free Survival for using STEEP criteria (Standardized Definitions for Efficacy End Points in adjuvant breast cancer trials) Ribociclib endocrine therapy Endocrine therapy Pre and postmenopausal women and men with HR-positive, HER2-negative EBC, after adequate surgical resection, who are eligible for adjuvant endocrine therapy Target Patients Read-out Milesstone(s) 2022 Publication TBD 111 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#112Participants Company overview Pharmaceuticals Financial performance Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations PiqrayⓇ - PI3K-alpha inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT04208178 EPIK-B2 (CBYL719G12301) HER-2 positive breast cancer Phase 3 548 Progression-free survival (PFS) Alpelisib + trastuzumab + pertuzumab Trastuzumab + pertuzumab Patients with HER2-positive advanced breast cancer with a PIK3CA mutation Read-out Milesstone(s) 2025 Publication TBD NCT04251533 EPIK-B3 (CBYL719H12301) Triple negative breast cancer Phase 3 566 Progression-free Survival (PFS) for patients with PIK3CA mutant status Alpelisib 300 mg + nab-paclitaxel 100 mg/m² Placebo nab-paclitaxel 100 mg/m² Patients with advanced triple negative breast cancer with either Phosphoinositide-3- kinase Catalytic Subunit Alpha (PIK3CA) mutation or Phosphatase and Tensin Homolog Protein (PTEN) loss without PIK3CA mutation 2023 TBD 112 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#113Participants Company overview Pharmaceuticals Financial performance Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations PiqrayⓇ - PI3K-alpha inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT04729387 EPIK-O (CBYL719K12301) Ovarian Cancer Phase 3 358 Progression Free Survival (PFS) based on Blinded Independent Review Committee (BIRC) assessment using RECIST 1.1 criteria Arm 1 Experimental: Alpelisib+olaparib: Alpelisib 200 mg orally once daily and olaparib 200 mg orally twice daily on a continuous dosing schedule Arm 2 Active Comparator: Paclitaxel or PLD. Investigator's choice of one of 2 single agent cytotoxic chemotherapies: Paclitaxel 80 mg/m2 intravenously weekly or Pegylated liposomal Doxorubicin (PLD) 40-50 mg/m2 (physician discretion) intravenously every 28 days. Patients with platinum resistant or refractory high-grade serous ovarian cancer, with no germline BRCA mutation detected Read-out Milesstone(s) 2023 Publication TBD 113 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#114Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD TabrectaⓇ - Inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT04427072 (CINC280A2301) Non-small cell lung cancer Phase 3 90 Progression free survival (PFS) per blinded independent review committee (BIRC) using RECIST v1.1 Arm 1: 400mg of capmatinib tablets administered orally twice daily Arm 2: Docetaxel 75 mg/m2 by intravenous infusion every 21 days Previously Treated Patients With EGFR wt, ALK Negative, Locally Advanced or Metastatic (Stage IIIB/IIIC or IV) NSCLC Harboring MET Exon 14 Skipping Mutation (MET?ex14). Primary 2022 Final: 2024 TBD NCT04816214 GEOMETRY-E (CINC280L12301) Non-small cell lung cancer Phase 3 245 Run-in part: Incidence of dose limiting toxicities (DLTs) Randomized part: Progression free survival (PFS) Arm 1: Experimental: Combination of capmatinib + osimertinib (run-in part). Arm 2: Experimental: Combination of capmatinib + osimertinib (randomized part) Arm 3: Active Comparator: platinum + pemetrexed based doublet chemotherapy Adult subjects with Non-small Cell Lung cancers as second line therapy Primary: 2025 Final: 2027 TBD 114 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#115Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations Tafinlar + MekinistⓇ - BRAF inhibitor and MEK inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04940052 (CDRB436J12301) Thyroid cancer Phase 3 150 Progression Free Survival Arm 1: Experimental: Dabrafenib plus trametinib Participants will be treated with dabrafenib twice daily and trametinib once daily Arm 2: Placebo Comparator: Placebo dabrafenib plus placebo trametinib Participants will receive placebo dabrafenib twice daily and placebo trametinib once daily Previously treated patients with locally advanced or metastatic, radio-active lodine refractory BRAFV600E mutation-positive differentiated thyroid cancer Target Patients Read-out Milesstone(s) 2024 Publication TBD 115 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#116Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations Tafinlar + MekinistⓇ - BRAF inhibitor and MEK inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT02684058 (CDRB436G2201) BRAFV600 mutant gliomas Phase 2 142 Objective response rate Dabrafenib + trametinib (dose based on age and weight) Children and adolescent patients with BRAF V600 mutation positive relapsed or refractory high grade glioma (HGG) or BRAF V600 mutation positive low grade glioma (LGG) Read-out Milesstone(s) 2022 Publication TBD 116 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#117Participants Company overview Pharmaceuticals Financial performance Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations Hematology 117 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#118Participants Company overview Pharmaceuticals Financial performance Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations AdakveoⓇ - Inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03814746 STAND (CSEG101A2301) Prevention of Vaso-Occlusive Crises (VOC) in patients with Sickle Cell Disease (SCD) Phase 3 240 Rate of VOC events leading to healthcare visit Crizanlizumab 5.0 mg/kg Crizanlizumab 7.5 mg/kg Placebo Adolescent and adult SCD patients (12 years and older) Target Patients Read-out Milesstone(s) 2022 Publication TBD 118 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#119Participants Company overview Pharmaceuticals Financial performance Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations AdakveoⓇ - P-selectin inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT03474965 SOLACE-Kids (CSEG101B2201) Prevention of VOC in pediatric patients with SCD Phase 2 100 PK/PD and safety of SEG101 at 5 mg/kg SEG101 (crizanlizumab) at a dose of 5 mg/kg by IV infusion ± Hydroxyurea/Hydroxycarbamide Pediatric SCD patients with VOC H2-2021 (pediatric patients >=12 year old) 2024 (pediatric patients <12 year old) Abstract submission to ASH 2021 119 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#120Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD JakaviⓇ - Inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03491215 REACH4 (CINC424F12201) Acute graft versus host disease Phase 2 45 Measurement of PK parameters Overall Response Rate (ORR) Ruxolitinib NCT03774082 REACH5 (CINC424G12201) Chronic graft versus host disease Phase 2 42 Overall Response Rate (ORR) Ruxolitinib 5mg tablets / pediatric formulation Pediatric patients with grade II-IV acute graft vs. host disease after allogeneic hematopoietic stem cell transplantation Pediatric subjects with moderate and severe chronic Graft vs. Host disease after allogeneic stem cell transplantation Target Patients Read-out Milesstone(s) 2023 Publication TBD 120 Investor Relations | Q3 2021 Results 2023 TBD NOVARTIS | Reimagining Medicine#121Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD JakaviⓇ - Inhibitor Study Indication Phase Patients NCT04097821 ADORE (CINC424H12201) Myelofibrosis Phase 1/2 130 Primary Outcome Measures Arms Intervention Incidence of dose limiting toxicities within the first 2 cycles Response rate at the end of cycle 6 Ruxolitinib Ruxolitinib+Siremadlin Ruxolitinib+Crizanlizumab Ruxolitinib+MBG453 Ruxolitinib+LTT462 Ruxolitinib+NIS793 Patients with Myelofibrosis (MF) Target Patients Read-out Milesstone(s) Publication 2024 TBD 121 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#122Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD KymriahⓇ - CD19 CAR-T Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03570892 BELINDA (CCTL019H2301) 2nd line Diffuse large B-cell lymphoma (DLBCL) Phase 3 318 Event-free Survival (EFS) Tisagenlecleucel versus standard of care Adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline- containing frontline immunochemotherapy Target Patients Read-out Milesstone(s) 9 Jul 2021 (actual) Publication Bishop et al at SITC 2019 Abstract submission TBD NCT03876769 CASSIOPEIA (CCTL019G2201J) 1st line high risk acute lymphoblastic leukemia (ALL) Phase 2 160 Disease Free Survival (DFS) Single-arm study of tisagenlecleucel Pediatric and young adult patients with 1st line high risk ALL 2025 TBD 122 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#123Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD PromactaⓇ - Thrombopoetin receptor agonist Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT03025698 (CETB115E2201) Refractory or relapsed severe aplastic anemia Phase 2 60 PK of eltrombopag at steady state in pediatric patients with SAA Eltrombopag 12.5, 25, 50, 75 mg FCT & 25 mg pFOS Arm A: relapsed/refractory SAA or recurrent AA following IST for SAA: hATG/cyclosporine + eltrombopag or cyclosporine + eltrombopag Arm B: previously untreated SAA: hATG/cyclosporine + eltrombopag Pediatric patients from age 1 <18 years with relapsed/refractory SAA or recurrent AA after IST or previously untreated SAA Primary CSR: 2022 Final CSR: 2025 TBD NCT03988608 (CETB115E2202) Refractory or relapsed severe aplastic anemia Phase 2 20 Hematologic response rate rate up to 26 weeks of treatment Eltrombopag 25 mg film-coated tablets Chinese patients with refractory or relapsed severe aplastic anemia Primary: 2021; Final: 2023 TBD 123 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#124Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD RydaptⓇ - Multi-targeted kinase inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03591510 (CPKC412A2218) Acute myeloid leukemia, pediatrics Phase 2 20 Occurrence of dose limiting toxicities Safety and Tolerability Chemotherapy followed by Midostaurin Newly diagnosed pediatric patients with FLT3 mutated acute myeloid leukemia (AML) Target Patients Read-out Milesstone(s) 2026 Publication TBD 124 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#125Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD asciminib - BCR-ABL inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04971226 ASC4FIRST (CABL001J12301) Chronic myeloid leukemia, 1st line Phase 3 402 Major Molecular Response (MMR) at week 48 Arm 1: asciminib 80 mg QD Arm 2: Investigator selected TKI including one of the below treatments: -Imatinib 400 mg QD - Nilotinib 300 mg BID - Dasatinib 100 mg QD - Bosutinib 400 mg QD Patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase Target Patients Read-out Milesstone(s) 2024 Publication TBD 125 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#126Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD iptacopan - CFB inhibitor - HEM Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT03439839 (CLNP023X2201) Paroxysmal nocturnal hemoglobinuria (PNH) Phase 2 16 Reduction of chronic hemolysis, based on LDH level at Week 13 10 patients receiving LNP023 high dose daily over up to approximately 3 years 5 patients receiving LNP023 low dose daily over up to approximately 3 years Patients with PNH, showing signs of active hemolysis despite treatment with SoC (defined as an antibody with anti C5 activity). Primary: Q2-2020 (actual) Extension: 2023 Antonio M. Risitano, MD, PhD1 et al. Presented at EBMT 2020 congress Jan 2021Pubs: Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial, Risitano, Antonio M et al. The Lancet Haematology, Volume 8, Issue 5, e344 - e354 NCT03896152 (CLNP023X2204) Paroxysmal nocturnal hemoglobinuria (PNH) Phase 2 13 Reduction of PNH associated hemolysis, based on percentage of patients with 60% reduction in LDH or LDH below upper limit of normal up to 12 weeks of treatment. approximately 2 year Treatment with low LNP023 dose approximately 2 year Treatment with higher LNP023 dose Patients with PNH, showing signs of active hemolysis, not treated with any other complement inhibitor less than 3 months prior to study start Day 1 Primary: Q2-2020 (actual) Extension: 2022 -Jang JH, et al. Presented at Korean Society of Hematology International Conference and 62nd Annual Meeting (ICKSH 2021) -Presented as an oral presentation (encore) at the European Haematology Association (EHA 2021) congress -Planned manuscript submission in Q3 2021 126 Investor Relations | Q3 2021 Results 1 NOVARTIS | Reimagining Medicine#127Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD iptacopan - CFB inhibitor - HEM Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT04558918 APPLY-PNH (CLNP023C12302) Paroxysmal nocturnal haemoglobinuria Phase 3 91 Percentage of participants achieving a sustained increase in hemoglobin levels of >= 2 g/dL in the absence of red blood cell transfusions Percentage of participants achieving sustained hemoglobin levels >= 12 g/dL in the absence of red blood cell transfusions Arm 1: Drug: LNP023, taken orally b.i.d. dosage supplied: 200 mg dosage form: hard gelatin capsule Route of Administration: Oral Arm 2: Drug: Eculizumab, administered as intravenous infusion every 2 weeks as per the stable regimen, the maintenance dose is a fixed dose. Dosage supplied: 300 mg/30mL Dosage form: Concentrate solution for infusion Drug: Ravulizumab, administered as intravenous infusion every 8 weeks, the maintenance dose is based on body weight. Dosage Supplied: 300 mg/30mL Dosage f Adult patients with PNH and residual anemia, despite treatment with an intravenous Anti-C5 antibody Primary 2022 Risitano AM, et al. Abstract accepted at the European Hematology Association (EHA 2021) congress (study design abstract; accepted for publication only) NCT04820530 APPOINT-PNH (CLNP023C12301) Paroxysmal nocturnal haemoglobinuria Phase 3 40 Proportion of participants achieving a sustained increase from baseline in hemoglobin levels of ? 2 g/dL assessed, in the absence of red blood cell transfusions Iptacopan (LNP023), taken orally b.i.d. (dosage supplied: 200mg) PNH patients who are naive to complement inhibitor therapy, including anti-C5 antibody 2023 Peffault de Latour R, et al. Abstract accepted at the European Hematology Association (EHA 2021) congress (study design abstract; accepted for publication only) 127 Investor Relations | Q3 2021 Results ✓ NOVARTIS | Reimagining Medicine#128Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD sabatolimab - TIM3 antagonist Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT03946670 STIMULUS MDS-1 (CMBG453B12201) Myelodysplastic syndrome Phase 2 120 Complete Remission (CR) rate and Progression Free Survival (PFS) Experimental: Sabatolimab (MBG453) + hypomethylating agents Placebo comparator: Placebo + hypomethylating agents Adult subjects with intermediate, high or very high risk Myelodysplastic Syndrome (MDS) as per IPSS-R criteria 2022-2023 NCT04150029 STIMULUS-AML1 (CMBG453C12201) Unfit acute myeloid leukaemia Phase 2 86 Incidence of dose limiting toxicities (Safety run-in patients only) Percentage of subjects achieving complete remission (CR) Single arm safety and efficacy study of sabatolimab in combination with azacitidine and venetoclax Newly diagnosed adult AML patients who are not suitable for treatment with intensive chemotherapy 2023 TBD 128 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#129Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD sabatolimab - TIM3 antagonist Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04266301 STIMULUS-MDS2 (CMBG453B12301) Myelodysplastic syndrome Phase 3 500 Overall survival Sabatolimab 800 mg + azacitidine 75 mg/m2 Sabatolimab 800 mg + azacitidine 75 mg/m2 + placebo Patients with intermediate, high or very high risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) Target Patients Read-out Milesstone(s) 2023 Publication TBD 129 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#130Participants Company overview Pharmaceuticals Financial performance Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations Biosimilars 130 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#131Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD aflibercept - VEGF inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04864834 Mylight (CSOK583A12301) Aflibercept BioS Phase 3 460 Best-corrected visual acuity (BCVA) will be assessed using the ETDRS testing charts at an initial distance of 4 meters. The change from baseline in BCVA in letters is defined as difference between BCVA score between week 8 and baseline Arm 1 Biological: SOK583A1 (40 mg/mL) Arm 2 Biological: Eylea EU (40 mg/mL) Patients with neovascular age-related macular degeneration Target Patients Read-out Milesstone(s) 2023 Publication tbd 131 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#132Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD denosumab - anti RANKL mAb Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03974100 (CGP24112301) Denosumab BioS Phase 3 522 Percent change from baseline (%CfB) in lumbar spine Bone Mineral Density GP2411 60 mg/mL subcutaneous injection every 6 months ProliaⓇ 60 mg/mL subcutaneous injection every 6 months Postmenopausal women with osteoporosis Target Patients Read-out Milesstone(s) 2022 Publication Study data publications expected for 2024 and beyond. The overall study design will be published at WCO and ECTS congresses 2020. 132 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#133Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD Global Health 133 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#134Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD artemether + lumefantrine - PGH-1 Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04300309 CALINA (CCOA566B2307) Malaria, uncomplicated (<5kg patients) Phase 3 Artemether Cmax Target Patients Read-out Milesstone(s) Publication Experimental: artemether lumefantrine (2.5 mg:30 mg) artemether lumefantrine (2.5 mg:30 mg) bid over 3 days, from 1-4 tablets per dose Infants and Neonates <5 kg body weight with acute uncomplicated plasmodium falciparum malaria Primary outcome measure: 2023 TBD 134 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#135Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD ganaplacide - Imidazolopiperazines derivative Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) Publication NCT03167242 (CKAF156A2202) Malaria Phase 2 PCR-corrected adequate clinical and parasitological response (ACPR) KAF156 and LUM-SDF (different combinations) Coartem Adults and children with uncomplicated Plasmodium falciparum malaria H2-2021 (actual) No new publications NCT04546633 KALUMI (CKAF156A2203) Malaria, uncomplicated Phase 2 PCR-corrected and uncorrected Adequate Clinical and Parasitological Response (ACPR) KAF156 and LUM-SDF QD (once daily) for 2 days in fasted condition KAF156 and LUM-SDF QD (once daily) for 2 days in fed condition Malaria patients 12 to < 18 years old with malaria caused by P. falciparum 2022 TBD 135 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine#136Participants Company overview Pharmaceuticals Financial performance Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations Abbreviations aHUS ALL ALS aBC AD Adj. AIH Advanced breast cancer Atopic Dermatitis Adjuvant Autoimmune hepatitis atypical Hemolytic Uremic Syndrome Acute lymphoblastic leukemia Amyotrophic lateral sclerosis HF-REF HNSCC HS ΙΑ IgAN iMN IPF AMI Acute myocardial infarction JIA AML Acute myeloid leukemia jPSA/ERA aNHL Agressive non-Hodgkin's lymphoma AS H2H Ankylosing spondylitis head-to-head study versus adalimumab LVEF mCRPC BC Breast cancer MDR C3G C3 glomerulopathy MDS CCF CINDU Congestive cardiac failure Chronic inducible urticaria MS NASH CLL CML Chronic lymphocytic leukemia Chronic myeloid leukemia nHCM nr-axSpA Chronic heart failure with reduced ejection fraction Head and neck squamous cell carcinoma Hidradenitis suppurativa Interim analysis IgA nephropathy Membranous nephropathy Idiopathic pulmonary fibrosis Juvenile idiopathic arthritis Juvenile psoriatic arthritis / enthesitis-related arthritis Left ventricular ejection fraction Metastatic castration-resistant prostate cancer Multi-drug resistant Myelodysplastic syndrome Multiple sclerosis Non-alcoholic steatohepatitis Non-obstructive hypertrophic cardiomyopathy Non-radiographic axial spondyloarthritis CRC Colorectal cancer COPD Chronic obstructive pulmonary disease NSCLC PEF Non-small cell lung cancer Preserved ejection fraction COSP Chronic ocular surface pain PedPsO Pediatric psoriasis CRSWNP Severe chronic rhinosinusitis with nasal polyps PNH CSU Chronic spontaneous urticaria PsA CVRR-Lp(a) CVRR-LDLC DME Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein (a) Secondary prevention of cardiovascular events in patients with elevated levels of LDLC Diabetic macular edema PROS RA rMS DLBCL ESCC FL GCA GVHD HCC HD HFPEF Diffuse large B-cell lymphoma refractory Esophageal squamous-cell carcinoma Follicular lymphoma Giant cell arteritis Graft-versus-host disease Hepatocellular carcinoma Huntington's disease Chronic heart failure with preserved ejection fraction RVO Retinal vein occlusion SAA SLE SpA SPMS TNBC T1DM Type 1 Diabetes mellitus SMA Type 1 SMA Type 2/3 Paroxysmal nocturnal haemoglobinuria Psoriatic arthritis PIK3CA related overgrowth spectrum Rheumatoid arthritis Relapsing multiple sclerosis Severe aplastic anemia Systemic lupus erythematosus Spinal muscular atrophy (IV formulation) Spinal muscular atrophy (IT formulation) Spondyloarthritis Secondary progressive multiple sclerosis Triple negative breast cancer 136 Investor Relations | Q3 2021 Results ✓ NOVARTIS | Reimagining Medicine#137Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References References Top-line results for CANOPY-1 1 2 3 4 5 Novartis Data on File ClinicalTrials.gov. Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A (Canopy-A). Available at: https://www.clinicaltrials.gov/ct2/show/NCT03447769. Accessed on September 10, 2021. Ridker PM, Thuren T, Zalewski A, et al. Interleukin-1ẞ inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162:597-605. ClinicalTrials.gov. Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1). Available at: https://clinicaltrials.gov/ct2/show/NCT03631199. Accessed on September 10, 2021. ClinicalTrials.gov. Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers. Available at: https://clinicaltrials.gov/ct2/show/NCT03798626. Accessed September 10, 2021 6 Jayaraman. P. Targeting IL-1ẞ pathway for cancer immunotherapy. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30 CosentyxⓇ peak sales expectations 1 2 Market defined as US + EU5 Biologics in PsO, PsA and AS. Source: US: IQVIA PADDS Monthly Jul'21 and Indication split% from SHS PTD for disease% for 2018 used for PSA, AS and IQVIA Medical for PSO. EU5- IQVIA Monthly Jul'21, CPO Inputs Jun'21 and IQVIA Padds Jul'21 PSO: DRG + IQVIA patient equivalents. SpA: Aligned with DRG and multiple internal sources EntrestoⓇgrew +44% in the quarter 1 2021 Update to the 2017 ACC Expert Consensus Decision Pathway (ECDP) for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. https://www.jacc.org/doi/10.1016/j.jacc.2020.11.022 2 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure https://doi.org/10.1093/eurhearti/ehab368 3 IQVIA National Prescription Audit as of 24/09/2021 EntrestoⓇ peak sales expectations 1 Eligible patients defined as prevalent HFrEF patients within each market's label. G7 = US, CA, JP, DE, FR, IT, UK 2 Including but not limited to CA, SP, UK LeqvioⓇ on track for US launch 1 In patients with elevated LDL-C despite treatment with maximally tolerated statin therapy. V-INITIATE NCT04929249; V-INCEPTION NCT04873934 137 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine